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Abstract 
Pregnancy-induced hypertension (PIH) with (pre-eclampsia) or without 
proteinuria has been found to be a state of insulin resistance and sympathetic 
over-activity. A hyperactive sympathetic nervous system may directly 
increase the risk of gestational hypertensive disorders, especially in 
overweight and obese women (Greenwood J 2003, Fischer T 2004, Wang Z 
2013) and altered metabolic functions can also result in an increased risk of 
pre-eclampsia in these women (Catalano P 2010). Angiopoietin-like protein 6 
(Angptl6) and adipocyte fatty acid-binding protein 4 (FABP4) seem to be 
insulin-sensitivity regulators and they could serve as insulin sensitivity 
biomarkers before and during complicated pregnancy. 
 
Material and methods 
This study consists of five sub-studies with four different study populations. 
In the first and second prospective observational studies there were 72 
relatively overweight (BMI ≥ 24 kg/m2) nulliparous women. In the study we 
assessed predictive parameters associated with subsequent pre-eclampsia. 
Insulin sensitivity was assessed via the Matsuda insulin sensitivity index 
(ISI) and by way of homeostatic model assessment of insulin resistance 
(HOMA-IR) at 24 weeks of gestation. Maternal serum levels of FABP4, high-
sensitivity C-reactive protein (hs-CRP), total testosterone, sex hormone-
binding globulin (SHBG) and non-protein bound calculated free testosterone 
(cfT), and plasma noradrenaline levels were determined at 24 and 32 weeks. 
In a subgroup of 47 women, serum concentrations of Angptl6 were 
quantified at 24 and 32 weeks of gestation. Of the study women, 14 
subsequently developed non-proteinuric PIH and 12 developed proteinuric 
PIH (pre-eclampsia), whereas 46 had normotensive pregnancies. 
In the third study there were 36 women. Eleven women with pre-
eclampsia were studied at 37 gestational weeks and they were compared with 
17 normotensive pregnant women studied at 38 gestational weeks and with 8 
non-pregnant women. Blood pressure was measured in different body 
positions and sympathetic activity was assessed by way of noradrenaline and 
adrenaline levels. Renin activity, natriuretic peptides and endothelin-1 were 
also assessed. 
In the fourth study the subjects were patients diagnosed at 26–32 
gestational weeks as having gestational diabetes mellitus (GDM). Diurnal 
blood glucose profiles were assessed in 178 women with GDM and they were 
classified as being normotensive (n = 102), having chronic hypertension (n = 
42) (with or without superimposed pre-eclampsia) or PIH (n = 34) (with or 
without proteinuria). Blood glucose profiles were analysed in the groups. 
In the fifth study, 18 women with a history of pre-eclamptic first 
pregnancy and 19 women with prior normotensive first pregnancies were 
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studied 23–24 years after delivery. Insulin sensitivity was assessed via the 
Matsuda whole-body ISI and serum concentrations of follicle-stimulating 
hormone (FSH), SHBG, total testosterone and cfT were assessed.  
 
Results 
In the first study systolic blood pressure (SBP) and plasma noradrenaline 
levels were higher at 32 weeks and FABP4 levels tended to be higher at 24 
and 32 weeks in women with subsequent PIH compared with normotensive 
controls. In logistic regression analysis, baseline FABP4 levels (p = 0.04, r2 = 
0.060) and SBP after 10 min standing (p = 0.02, r2 = 0.085) were associated 
with the development of PIH.  
In the second study, serum Angptl6 levels at 24 weeks, but not at 32 
weeks, were significantly higher in women with subsequent PIH compared 
with normotensive controls (median 252, range 85–536 ng/ml vs. 145, 28–
455 ng/ml, p = 0.02). Angptl6 levels did not correlate with metabolic factors.  
In the third study plasma noradrenaline levels were higher in pre-
eclamptic women than in normotensive pregnant women and the difference 
was most obvious when they were in an upright position.  
In the fourth study hypertension complicated 43% of the pregnancies of 
women with GDM. The glucose profiles were similar in women with 
normotensive pregnancy, chronic hypertension and PIH, except that in early 
morning hours (from 04:oo to 08:00 hours) blood glucose concentrations 
increased in mothers with chronic hypertension, whereas they decreased in 
the normotensive women.  
In the fifth study insulin sensitivity and total and free testosterone were 
similar in the two groups. However, in women with prior pre-eclampsia and 
FSH levels below the median, cfT levels were higher than in women with 
prior pre-eclampsia and FSH levels above the median (median 13.4 pmol/l, 
range 8.0–22.5, vs. 7.1 pmol/l, range 5.1–20.5, p = 0.03), while this kind of 
difference was not seen in women with prior normotensive pregnancies. Of 
the women with previous pre-eclampsia, 17% (3/18) had metabolic syndrome 
and 11% (2/18) had polycystic ovary syndrome, vs. 11% (2/19) and 0% of the 
controls, respectively. 
 
Conclusions 
In this study there was some evidence that pre-eclampsia was associated with 
sympathetic over-activity and some signs of it could be seen as early as in the 
third trimester of pregnancy in women with subsequent PIH.  However, 
there was no evidence of increased insulin resistance or hyperandrogenism 
before PIH or 23–24 years after pre-eclamptic pregnancy. The results 
suggest that Angptl6 and FABP4, regulators of insulin sensitivity, could be 
associated with subsequent PIH to some extent, but there was no association 
between Angptl6 and FABP4 levels and insulin sensitivity markers. The role 
and significance of these proteins in the pathogenesis of PIH remain 
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unknown. Our results strengthen the concept of a potential role of angiogenic 
and angiogenic-like factors in the pathogenesis of pre-eclampsia.   
The data support the hypothesis of the presence of sympathetic over-
activity in hypertensive pregnancy. It is suggested that Angptl6 and FABP4, 
regulators of insulin sensitivity, may have a potential role in the development 
of PIH. 
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INTRODUCTION 
Pregnancy-induced hypertension (PIH) and pre-eclampsia have been found 
to be characterized by insulin resistance (Seely E 2003, Roberts J 2011), 
sympathetic over-activity (Schobel H 1996, Greenwood J 2003) and 
exaggerated systemic inflammation (Wolf M 2001, Seely E 2003), all features 
of metabolic syndrome (Lambert G 2010). In women, metabolic syndrome is 
an important risk factor of cardiovascular disease (CVD) (Galassi A 2006). 
Hypertensive pregnant women are at an increased risk of later CVD and 
mortality (Bellamy L 2007, Valdiviezo C 2012), regardless of their proteinuric 
status (Männistö T 2013). In particular, women with both hypertensive 
disorders of pregnancy and gestational diabetes mellitus (GDM) are at an 
increased risk of future CVD (Sullivan S 2011). 
Pre-pregnancy adiposity is a risk factor of non-proteinuric PIH (Sukalich 
S 2006) and proteinuric pre-eclampsia (Roberts J 2011, Wang Z 2013). In 
non-pregnant individuals a key protein linking obesity to various features of 
metabolic syndrome is adipocyte fatty acid-binding protein 4 (FABP4) (Xu A 
2007). This intracytoplasmic lipid chaperone (Furuhashi M 2008) is actively 
secreted into the blood stream (Xu A 2006) to control liver glucose 
metabolism (Cao H 2013). Moreover, FABP4 integrates metabolic and 
inflammatory response systems (Furuhashi M 2011). In pre-eclampsia 
maternal FABP4 levels are elevated (Fasshauer M 2008, Shangguan X 2009, 
Scifres C 2012). 
Angiopoietin-like protein 6 (Angptl6) is a liver-derived pro-angiogenic 
protein, which is an insulin-sensitivity regulator independent of its pro-
angiogenic effect. This protein tends to prevent the establishment of related 
metabolic diseases – at least in animal experiments (Oike Y 2005). In human 
studies, circulating levels of Angptl6 are elevated in insulin-resistant states 
such obesity, diabetes (Ebert T 2009) and metabolic syndrome (Namkung J 
2011). Like other pro-angiogenic factors (Stepan H 2007), serum Angptl6 
might be expected to be reduced in pre-eclampsia, but serum Angptl6 levels 
have been found to be elevated in pre-eclamptic women (Stepan H 2009). 
However, in a recent study, maternal Angptl6 levels were elevated during 
pregnancy, but not more in pre-eclamptic compared with normotensive 
pregnant women (Xia G 2013).  
Overall, data on the role of Angptl6 in pre-eclampsia is scarce and mixed 
(Stepan H 2009, Xia G 2013) and in non-proteinuric PIH, unknown. The role 
of FABP4 in the pathogenesis of pre-eclampsia is still incompletely 
understood (Fasshauer M 2008) and its role in non-proteinuric PIH lacking. 
It has also remained unclear if increased sympathetic activity precedes pre-
eclampsia, whether it represents only a secondary phenomenon (Fischer T 
2004) or whether it appears before insulin resistance (Kaaja R 2006). 
Metabolic changes at the end of the reproductive years of a woman´s life are 
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less well recognized than in the postmenopausal period (Spencer C 1997), 
especially in women with a history of pre-eclampsia. 
 
In the first study we aimed to clarify the possible role of FABP4 in pre-
eclampsia by assessing maternal FABP4 levels in the second and third 
trimesters of pregnancy before clinical onset of the condition. We also sought 
associations between maternal serum FABP4 levels and indices of possible 
insulin resistance, sympathetic over-activity, inflammation and 
hyperandrogenism in cases of PIH. In the second study, accordingly, we 
aimed to clarify if there was an association between maternal serum Angptl6 
levels and indices of possible insulin resistance and sympathetic over-activity 
in cases of PIH. In the first and the second studies we also aimed to assess if 
maternal serum Angptl6 and FABP4 levels were associated with subsequent 
development of hypertensive pregnancy.  
In the third study we hypothesized that body posture might magnify 
differences in neurohormonal indices, especially plasma noradrenaline, 
between pre-eclamptic and normotensive controls. We studied 
neurohormone indices in connection with different body postures in women 
with pre-eclampsia, in normotensive pregnant women and in non-pregnant 
women. 
Our fourth study involved testing the hypothesis that diurnal glucose 
profiles differ in women with GDM and different forms of hypertensive 
complications. We investigated 24-hour glucose profiles in women with GDM 
and/or pregnancy-related hypertensive complications. 
In the fifth study our hypothesis was that in premenopausal women with a 
history of pre-eclampsia there are more signs of insulin resistance, metabolic 
syndrome and polycystic ovary sydrome (PCOS) than in women with a 
history of normotensive pregnancies. We assessed insulin sensitivity, 
metabolic syndrome and signs of hyperandrogenism 23–24 years after pre-
eclamptic and normotensive pregnancies. 
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1 HYPERTENSIVE PREGNANCY 
1.1 DEFINITION AND CLASSIFICATION 
Hypertension is a common medical problem encountered during pregnancy, 
complicating 6–8% of pregnancies (National 2000). Hypertensive disorders 
during pregnancy are classified into four categories, as recommended by the 
National High Blood Pressure Education Program Working Group on High 
Blood Pressure in Pregnancy (National 2000), listed in Table 1. 
New-onset hypertension, non-proteinuric PIH or proteinuric PIH (pre-
eclampsia), develops in up to 5% of previously normotensive women after 20 
weeks of gestation (Seely E 2003). In these women, hypertension develops 
during the second half of pregnancy, usually during the third trimester, and 
resolves typically within 6 weeks postpartum (Seely E 2003). Pregnancy-
induced hypertension is defined as systolic blood pressure (SBP) elevation to 
≥ 140 mmHg or diastolic BP (DBP) elevation to ≥ 90 mmHg on at least two 
occasions and at least 4–6 h apart in women who were normotensive before 
20 weeks of gestation. Proteinuria is defined as the urinary excretion of ≥ 0.3 
g protein in a 24-hour specimen. This usually correlates with ≥ 30 mg 
protein/dl (≥ 1+ reading on a dipstick) in a random urine determination 
(National 2000). Non-proteinuric PIH and pre-eclampsia have the same cut-
off values for blood pressure, but differ regarding proteinuria. 
Table 1. Classification of hypertensive disorders in pregnancy (National 2000). 
 Definition 
Proteinuric PIH (pre-eclampsia) Hypertension developing after 20 weeks of gestation 
with proteinuria 
Non-proteinuric PIH, also termed  
gestational hypertension or 
transient hypertension of 
pregnancy 
Hypertension developing after 20 weeks of gestation 
without proteinuria/other signs of pre-eclampsia 
Chronic hypertension Hypertension before 20 weeks of gestation 
Superimposed pre-eclampsia Pre-eclampsia developing in a women with pre-
existing hypertension 
PIH; Pregnancy-induced hypertension. 
 
Chronic hypertension is long-term hypertension, antedating pregnancy 
and persisting afterwards. It is defined as SBP elevated to ≥ 140 mmHg 
systolic or DBP elevated to ≥ 90 mmHg. Hypertension that is diagnosed for 
the first time during pregnancy and that does not resolve postpartum is also 
classified as chronic hypertension. In superimposed pre-eclampsia, pre-
eclampsia develops in a woman with chronic hypertension (National 2000). 
Hypertensive pregnancy 
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The majority of women with pre-existing hypertension do well in pregnancy. 
However, about 20% of them develop superimposed pre-eclampsia (Seely E 
2003). On the other hand, after late first trimester, blood pressure levels may 
be normal in women with chronic hypertension, since blood pressure usually 
falls in the late first to early second trimester and rises to pre-pregnancy 
levels in the third trimester (Seely E 2003).  
Women with GDM are at an increased risk of hypertensive disorders 
during pregnancy (Joffe G 1998, Bryson C 2003, Sullivan S 2011). These 
women have more chronic hypertension (Suhonen L 1993, Sullivan S 2011) 
and non-proteinuric PIH (Bryson C 2003) and 10–30% of women with GDM 
develop proteinuric pre-eclampsia (Yogev Y 2004, Montroro M 2005). The 
risk of pre-eclampsia among women with GDM increases with the severity of 
GDM and with pre-pregnancy obesity (Yogev Y 2004). One in five women 
with GDM developed non-proteinuric or proteinuric PIH in a Finnish study 
(Suhonen L 1993). 
 
Generally, non-proteinuric PIH is a relatively benign disorder (Seely E 
2003). In the absence of severe disease manifestations, discriminating 
between non-proteinuric PIH and pre-eclampsia may be difficult (Solomon C 
2001). Non-proteinuric PIH and proteinuric PIH (pre-eclampsia) are often 
seen as a continuum of the same disease, since they share many risk factors 
(Villar 2006) and the pathogenesis of the diseases is similar (Seely E 2003). 
Although it is unclear whether they are separate conditions (Seely E 2003), 
proteinuric PIH is associated with endothelial dysfunction (Franceschini N 
2005), which is less evident in non-proteinuric PIH (Powers R 2001). On the 
other hand, sympathetic over-activity has not been found to be greater in 
pre-eclampsia compared with non-proteinuric PIH (Greenwood J 2003).  
Proteinuric PIH is defined as a systemic syndrome, which includes a 
combination of maternal hypertension and proteinuria. Other systemic 
manifestations include disseminated intravascular coagulation, haemolysis, 
elevated liver function test results, and (rarely) seizures (eclampsia) (Turner 
J 2010). The clinical presentation of pre-eclampsia is highly variable. In 
serious pre-eclampsia severe hypertension is associated with proteinuria, or 
significant end-organ disease is associated with even mild hypertension 
(Turner J 2010). Hypertension is regarded as severe if SBP is sustained at ≥ 
160 mmHg or DBP is sustained at ≥ 110 mmHg, or both (Turner J 2010, 
Sibai B 2005). The clinical progression of the disease may worsen from mild 
to severe, or to eclampsia, without warning, or may be severe at the time of 
diagnosis (Turner J 2010). Instead of the classic “mild” versus “severe” 
terminology, “early” (< 34 weeks of gestation) versus “late” (symptoms > 34 
weeks of gestation) pre-eclampsia terminology is becoming an indicator of 
disease significance (Tranquilli A 2013). 
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1.1.1 EPIDEMIOLOGY AND CLINICAL RISK FACTORS 
Proteinuric pre-eclampsia is probably a multifactorial and heterogeneous 
disease entity, but the majority of cases occur in previously healthy 
nulliparous women (Sibai B 2005). The incidence in nulliparous women 
ranges from 2 to 7% and 75% of them have mild disease (Sibai B 2005). In all 
pregnancies the incidence ranges up to 5% to 8% (Turner J 2010), although 
certain subpopulations experience much higher incidence rates (Sibai B 
2005). A risk population in Finland showed an 18.3% incidence of pre-
eclampsia (Villa P 2013). Table 2 shows maternal and pregnancy 
characteristics that have been identified as risk factors of pre-eclampsia. 
Table 2. Risk factors of pre-eclampsia (adapted from Sibai B 2005, Turner J 2010) 
Maternal obstetric factors: 
? Nulliparity 
? Extremes of maternal age 
? Pre-eclampsia in a previous pregnancy 
? Pregnancies after donor insemination, oocyte donation, embryo donation 
? Multi-foetal gestation 
? Molar pregnancy 
Maternal comorbid conditions: 
? Chronic hypertension 
? Pre-gestational vascular/endothelial/renal disease 
? Pre-gestational diabetes 
? Rheumatic disease 
? Infections 
Maternal genetic factors: 
? Anti-phospholipid antibodies 
? Factor V Leiden mutation (protein C resistance) 
? First-degree relative with a pre-eclamptic pregnancy 
? African-American race 
? Maternal low birth weight 
Maternal lifestyle factors: 
? Obesity 
? Smoking (reduced risk) 
Paternal obstetric factors: 
? Limited sperm exposure  
? Primipaternity 
? Paternity by male who fathered a previous pre-eclamptic pregnancy in another 
woman 
? Paternity by a male born from a pre-eclamptic pregnancy 
 
Early-onset pre-eclampsia has been more strongly associated with 
African-American race, chronic hypertension and congenital anomalies 
Hypertensive pregnancy 
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(Lisonkova S 2013), whereas younger maternal age, nulliparity, and diabetes 
mellitus have been associated with late-onset disease (Lisonkova S 2013). 
The role of a high body mass index (BMI) on disease onset has been 
controversial (Valensise H 2008, Lisonkova S 2013). Obesity seems to 
increase the risk of all “forms” of pre-eclampsia (Roberts R 2011). Pre-
pregnancy adiposity is a strong independent risk factor of both proteinuric 
and non-proteinuric PIH (Sukalich S 2006, Roberts J 2011). Among obese 
pregnant women about 10% develop proteinuric PIH (Roberts J 2011). The 
underlying mechanism connecting obesity and pre-eclampsia is still 
incompletely understood (Roberts R 2011, Catalano P 2010).  
1.1.2 PATHOPHYSIOLOGY 
The exact pathophysiology of pre-eclampsia remains undefined and can 
differ in women with various risk factors (Sibai B 2005). A central 
mechanism in the pathogenesis of pre-eclampsia is endothelial dysfunction. 
In pre-eclampsia endothelial dysfunction is involved in placental and 
systemic circulations (Solomon C 2006), but the target organ is maternal 
endothelium (Young B 2010). It is thought that endothelial abnormalities 
impairing renal natriuresis and increasing total peripheral resistance (TPR) 
cause hypertension (Gilbert J 2008). Other signs of endothelial dysfunction 
in pre-eclampsia include proteinuria, microangiopathic haemolytic anaemia 
and organ hypoperfusion (Salomon C 2006). In addition to endothelial 
dysfunction, perturbation of the renin-aldosterone-angiotensin II axis, 
excessive oxidative stress, inflammation, immune maladaptation, and 
genetic susceptibility may all contribute to the pathogenesis of pre-eclampsia 
(Young B 2010). 
The pathophysiology may also differ according to the time of onset of the 
disorder (Sibai B 2005). Late-onset pre-eclampsia is referred to as maternal 
pre-eclampsia and early-onset disease is referred to as placental pre-
eclampsia. The latter emphasizes the central role of poor placentation in 
early-onset disease (Redman C 2005).  
 
Placental pre-eclampsia 
Abnormal placentation is thought to start with early-onset, placental pre-
eclampsia (Redman C 2005). The onset of placental pre-eclampsia is 
typically < 34 weeks of gestation and women have no cardiovascular risk 
factors (Oudejans C 2007). Placental pre-eclampsia is associated with 
intrauterine growth retardation and abnormal placental morphology 
(Oudejans C 2007). 
Since hypertension in pre-eclampsia develops during the third trimester 
and resolves after delivery, the placenta is thought to play a central role in 
the disease (Redman C 2005, Staff A 2013). A placental or maternal reaction 
to placentation is the fundamental error in placental pre-eclampsia. A 
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placental disorder carries a high recurrence risk, and runs in families, with a 
clear genetic component (Oudejans C 2007). 
In normal placentation embryo-derived cytotrophoblasts invade the 
placental bed, where they come into contact with maternal tissues. The distal 
ends of the maternal spiral arteries are then transformed into widely dilated, 
structureless conduits (Redman C 2005) with low resistance.  
In pre-eclampsia, in contrast, trophoblast invasion is shallow and spiral 
arteries are not remodelled appropriately (Kanasaki K 2009). Spiral artery 
blood flow remains in a state of high resistance and low flow, with resulting 
hypoperfusion and hypoxaemia of the placenta (Redman C 2005, Roberts J 
2005, Kanasaki K 2009). Placental ischaemia is widely regarded as a key 
factor in pre-eclampsia (Gilbert J 2008). Hypoxia and chronic inflammation 
induce up-regulation of placental inflammatory cytokines such as tumour 
necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6), increase synthesis of 
anti-angiogenic soluble fms-like tyrosine kinase-1 (sFlt-1) and increase 
circulating vasoactive factors angiotensin II type 1 receptor autoantibodies 
(AT1-AA), and thromboxane (TX). Elevations of these soluble factors are 
thought to result in endothelial dysfunction in maternal vasculature (Gilbert 
J 2008). 
 
Maternal pre-eclampsia 
In turn, most cases of late-onset pre-eclampsia might rather be considered 
mainly as maternal disorders (Egbor M 2006, Oudejans C 2007). In this 
disorder the placenta may lack abnormal placental morphology typical of 
early onset pre-eclampsia (Egbor M 2006). The clinical disease of maternal 
pre-eclampsia may arise from interaction between a possibly normal 
placenta and a predisposed maternal constitution reflecting microvascular 
disease, as occurs with long-term hypertension, diabetes or other states of 
metabolic unbalance, or reflecting a maternal genetic predisposition 
(Oudejans C 2007).   
Late-onset disease is associated with more favourable outcomes 
(Valensise H 2008) and with much milder endothelial dysfunction than in 
early-onset pre-eclampsia (Gilbert J 2008), supporting the idea that the 
pathophysiology is different in these two diseases (Valensise H 2008). 
1.1.3 MATERNAL HAEMODYNAMICS 
During pregnancy profound changes take place in maternal haemodynamics 
(Table 3). The autonomic nervous system (ANS) plays a central role in 
adaptation of the cardiovascular system to various haemodynamic needs and 
is the principal system in short-term cardiovascular control (Ekholm E 
1996).  
Compared with normal pregnancy, in pre-eclampsia vascular resistance is 
increased in the foeto-placental circulation, there are constricted vessels 
Hypertensive pregnancy 
22 
(Kanasaki K 2009), plasma volume is lower, renin expression increased 
(Shah D 2005) and plasma renin activity lower (Kanasaki K 2009) (Table 3). 
Table 3. Maternal haemodynamics in normal and pre-eclamptic pregnancies 
 
Normal pregnancy 
versus non-pregnant 
Pre-eclampsia versus 
normal pregnancy 
Reference 
BP 
SBP 
DBP 
MAP 
Slightly decreased 
minimal changes 
evident decrease 
Decreased 
Increased strongly 
 
 
Increased 
Kanasaki K 2009, 
Rang S 2002 
HR Increased Decreased Rang S 2002 
CO 
 
Increased Reduced Rang S 2002 
SVR Decreased 
(vascular dilatation) 
Increased strongly 
(vascular contraction) 
Rang S 2002, 
Kanasaki K 2009 
Plasma 
volume 
Increased Decreased Rang S 2002, 
Shah D 2005 
Uterine blood 
flow 
Increased Reduced Thornburg K 
2000, Shah D 
2005 
Renal plasma 
flow 
Increased Decreased Thornburg K 
2000, Moran P 
2003 
RAS Increased  Lower   Shah D 2005 
BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, 
mean arterial pressure; HR, heart rate; CO, cardiac output; SVR, systemic vascular 
resistance; RAS, renin-angiotensin system. 
 
Normal pregnancy is characterized by resistance to the vasoconstrictive 
effects of angiotensin II. In non-proteinuric and proteinuric PIH, this 
resistance is blunted, resulting in increased sensitivity to angiotensin II 
(Kanasaksi K 2009, Powe C 2011).  
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1.2 METABOLIC CHARACTERISTICS 
1.2.1 INSULIN RESISTANCE 
All pregnancies are characterized by some level of insulin resistance (Seely E 
2003). The relative glucose intolerance helps to maintain continuous glucose 
transfer to the foetus, which requires 80% of its energy as glucose, even if 
maternal postprandial plasma glucose levels decrease, and during fasting. In 
early gestation insulin secretion increases, whereas insulin sensitivity is 
unchanged, decreased or even increased (Barbour L 2007). From mid-
pregnancy onwards insulin sensitivity gradually decreases, being lowest in 
the third trimester. As a result, a 2- to 2.5-fold increase in insulin secretion is 
necessary to maintain euglycaemia (Barbour L 2007). In late pregnancy the 
insulin-mediated glucose disposal rate declines and insulin shows reduced 
ability to suppress lipolysis. 
Dietary or endogenous glucose stimulates insulin secretion by the β-cells 
of the pancreas. Insulin increases glucose uptake by fat and muscle, 
decreases glucose production by the liver, and inhibits lipolysis. Insulin 
resistance or decreased insulin sensitivity is characterized by the impaired 
action of insulin in insulin-sensitive target tissues such as muscle, liver, 
adipose tissue and endothelium. A compensatory state of insulin resistance is 
adaptive hyperinsulinaemia, which forestalls the development of 
hyperglycaemia and subsequent diabetes (Lau D 2005).  
Resistance to insulin can be characterized at a pre-receptor level (insulin 
antibodies), a receptor level (decreased number of receptors on the cell 
surface), or a post-receptor level (defects in the intracellular insulin 
signalling pathway) (Catalano P 2010). In pregnancy, decreased insulin 
sensitivity is characterized as post-receptor defect (Ryan E 1988, Catalano P 
2010). 
Because insulin resistance and resultant hyperinsulinaemia progress as 
the placenta develops, insulin resistance is probably mediated by placenta-
derived hormones, including human placental lactogen, progesterone, 
cortisol, estradiol, human placental growth hormone and prolactin (Ryan E 
1988, Briana D 2009). Pregnancy-associated insulin resistance has been also 
related to free fatty acids (FFAs), peroxisome proliferator-activated 
receptors, leptin, TNF-α, IL-6, adiponectin and resistin (Zavalza-Gómez A 
2008). Recently the role of adipokines has been highlighted.  
1.2.2 PIH AND INSULIN RESISTANCE 
The features of the mother must also be considered in the pathophysiology of 
pre-eclampsia, since several similar metabolic abnormalities that are thought 
to predispose women to the development of pre-eclampsia are observed in 
the non-pregnant state in women who have had pre-eclampsia (Seely E 
2003). One of those metabolic factors that may play a role in the 
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pathogenesis of PIH is insulin resistance (Seely E 2003). Hyperinsulinaemia 
may directly predispose women to hypertension by increasing renal sodium 
reabsorption and stimulating the sympathetic nervous system (Seely E 
2003). Insulin resistance could contribute to endothelial dysfunction in pre-
eclampsia (Seely E 2003, Gilbert J 2008). However, the precise role of 
insulin resistance in the development of pre-eclampsia and non-proteinuric 
PIH remains undetermined (Seely E 2003, Gilbert J 2008). 
As early as in the first trimester women with subsequent late-onset pre-
eclampsia have been found to be more insulin resistant compared with early-
onset and normotensive groups (D'Anna R 2006). Maternal mid-trimester 
insulin resistance has been associated with subsequent pre-eclampsia (Hauth 
J 2011).  
In non-proteinuric (Seely E 2003) and proteinuric PIH, insulin resistance 
is enhanced (Kaaja R 1999a, Seely E 2003). In mild pre-eclampsia increased 
insulin levels have been observed independently of a maternal overweight 
condition (Moran C 2006). In established pre-eclampsia, women have been 
found to have higher levels of insulin and glucose, increased levels of 
triglycerides and FFAs and elevated levels of cytokines (e.g. TNF-α) 
associated with the insulin resistance (Salomon C 2006).  
Pregnant women with both insulin-resistant chronic hypertension and 
GDM (Buchanan T 1990) may be more insulin-resistant than those with 
GDM alone (Caruso A 1999). In GDM a central component of the 
pathophysiology is chronic insulin resistance (Barbour L 2007). However, in 
one study, women with GDM who developed pre-eclampsia were not more 
insulin resistant than those who remained non-pre-eclamptic (Montoro M 
2005).  
Although insulin sensitivity improves postpartum, women have had 
decreased insulin sensitivity for at least three months after pre-eclamptic 
pregnancy (Kaaja R 1999a). 
  
 25 
1.2.3 FATTY ACID-BINDING PROTEIN 4 
 
Adipocytokines 
Adipose tissue-derived proinflammatory mediators may directly contribute 
to insulin resistance, vascular injury and atherogenesis (Lau D 2005). These 
proinflammatory adipocytokines, or adipokines, include TNF-α, IL-6, leptin, 
plasminogen activator inhibitor-1 (PAI-1), angiotensinogen, resistin and C-
reactive protein (CRP). Adipokines link obesity to insulin resistance in 
metabolic syndrome and endothelial dysfunction (Figure 1). They may 
directly influence endothelial function through their proinflammatory 
properties (Lau D 2005).  
Fatty acid-binding protein 4 is a novel adipokine that maintains glucose 
homeostasis (Furuhashi M 2008). In non-pregnant individuals various 
features of metabolic syndrome are linked to obesity by FABP4 (Xu A 2007). 
Figure 1 Adipokines are cellular mediators that link obesity to insulin resistance in metabolic 
syndrome, and endothelial dysfunction (adapted from Lau D 2005)
 
Fatty acid-binding proteins (FABPs)  
Lipid-binding proteins facilitate solubility and the translocation of 
hydrophobic ligands in intra- and extracellular fluids (Zimmerman A2002). 
Cytoplasmic fatty acid-binding proteins (FABPs) are lipid chaperones that 
coordinate fatty acid transport and utilization in adipocytes, macrophages, 
trophoblasts, human placental endothelial capillary cells (Furunhasi M 2008, 
Scifres C 2011) and microvascular endothelial cells (Elmasri H 2009). At 
least 9 different FABP isoforms have been identified (Furuhashi M 2011). 
FABPs derived from metabolically active cells regulate inflammatory and 
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metabolic responses mainly in adipocytes and macrophages (Furuhashi M 
2011). A member of the FABP family (Zimmerman A 2002) expressed in both 
adipocytes and macrophages is fatty acid-binding protein 4 (Furuhashi M 
2008).  
 
Fatty acid binding protein 4 (FABP4) 
FABP4, also known as adipocyte fatty acid-binding protein (A-FABP) or 
adipocyte P2 (aP2), is mainly expressed in adipocytes (Furuhashi M 2008) 
where it chaperones FFAs in lipolysis (Furuhashi M 2008). Lipolytic signals, 
β-adrenergic stimuli and signals of fasting regulate synthesis of FABP4 (Cao 
H 2013).  
During fasting a key energy source is serum FFAs (Cao H 2013). From 
serum, FFAs are taken up in muscle to be oxidized. In muscle, FFAs reduce 
glucose uptake. In the liver FFAs activate glucose production (Cao H 2013) 
by increasing gluconeogenesis and lipogenesis. The increase in plasma free 
fatty acids is especially relevant, as they cause insulin resistance. In muscle, 
excess fatty acids reduce insulin-mediated glucose utilization and in liver 
they inhibit insulin-mediated suppression of glucose production (Cao H 
2013). 
In early gestation free fatty acid concentrations are lower than later in 
pregnancy. In late pregnancy maternal adipose tissue depots decrease and 
postprandial FFA levels are increased (Barbour L 2007). In pre-eclampsia 
triglyceride-rich lipoproteins and circulating FFAs are increased. Levels of 
FFAs are increased even before the clinical onset of pre-eclamptic symptoms 
(Kaaja R 2011).  
From mature adipocytes FABP4 is actively secreted into the bloodstream 
(Xu A 2006, Furuhashi M 2008). In FABP4-null mice both basal and 
hormone-stimulated lipolysis is impaired and they are protected from insulin 
resistance induced by dietary and genetic obesity, suggesting that this lipid 
chaperone is also involved in regulating insulin sensitivity (Furuhashi M 
2008, Xu A 2012). In primary hepatocytes in vitro and in lean mice in vivo, 
recombinant FABP4 stimulates glucose production and gluconeogenic 
activity, providing evidence that FABP4 controls liver glucose metabolism 
(Cao H 2013). 
In mice, FABP4 is also expressed in plaque macrophages (Furuhashi M 
2007), where it modulates cholesterol ester accumulation and foam cell 
formation (Furuhashi M 2011). FABP4 could function as a mediator at the 
interface of lipid metabolism and inflammatory responses in atherosclerotic 
disease (Furuhashi M 2011, Pastenkamp G 2012). 
 
FABP4, metabolic risk factors and CVD 
In overweight and obese individuals circulating FABP4 levels have been 
found to be markedly elevated (Xu A 2006) and they correlated strongly with 
body mass index (Cao H 2013). Elevation of serum FABP4 has also been 
associated with various obesity-related cardiometabolic risk factors such as 
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atherogenic dyslipidaemia, insulin resistance (Xu A 2006), hyperglycaemia 
(Tso A 2007) and hypertension (Ota H 2012), which are key components of 
metabolic syndrome. High FABP4 concentrations have been reported to be 
predictive as regards the development of metabolic syndrome, independently 
of adiposity and insulin resistance (Xu A 2007) and also as regards the 
development of DM2, again independently of obesity and insulin resistance 
(Tso A 2007).  
In pregnancy-specific glucose disturbance, GDM, maternal FABP4 levels 
have been found to be increased (Kralisch S 2009). Serum levels of FABP4 
have also been associated with atherosclerosis (Peeters W 2011), endothelial 
dysfunction (Lee M 2011) and macrovascular complications of diabetes (Xu A 
2012).  
FABP4 possibly potentiates lipid-induced inflammation in obesity-related 
cardiovascular disease. The inflammatory status of atherosclerotic lesions is 
a major factor triggering acute cardiovascular events. Plasma FABP4 levels 
have been reported to be an independent risk factor of vascular inflammation 
and they correlated positively with those of several proinflammatory markers 
(high sensitivity CRP (hs-CRP), TNF-α receptors and IL-6) (Xu A 2012). 
Among subjects who underwent carotid endarterectomy, FABP4 levels were 
associated with an unstable plaque phenotype and were predictive of the 
occurrence of an adverse outcome in CVD (Peeters W 2011). In patients with 
ischaemic stroke FABP4 has served as prognostic indicator of early mortality 
(Tso A 2011). After adjustment for traditional risk factors, FABP4 levels have 
been predictive of the development of CVD (Chow W 2013). 
 
FABP4 and hypertensive pregnancy 
Maternal circulating FABP4 levels have been reported to be elevated in 
proteinuric pre-eclampsia (Fasshauer M 2008, Shangguan X 2009), even 
before the clinical onset of the disease (Scifres C 2012). Maternal serum 
FABP4 levels have been found to be elevated independently of maternal body 
mass index (Scifres C 2012). 
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1.3 SYMPATHETIC ACTIVITY 
 
Autonomic nervous system (ANS) 
The autonomic nervous system (ANS) mediates neuronal regulation of the 
internal milieu, primarily the smooth musculature of all organs. The highest 
integrative organ of the ANS is the hypothalamus. With hypophyseal 
connections, the hypothalamus also regulates the endocrine glands and 
coordinates the autonomic nervous and endocrine systems. The peripheral 
ANS consists of sympathetic, parasympathetic and enteric nervous systems 
(Schmidt R 1989).  
In most situations sympathetic and parasympathetic systems act 
“synergistically” to regulate organ function and to cope with environmental 
variations. However, various pathological conditions such as cardiovascular 
disease are associated with an autonomic imbalance, characterized by a 
hyperactive sympathetic system and a hypoactive parasympathetic system 
(Thayer J 2010). 
 
Sympathetic nervous system 
The sympathetic nervous system is widely recognized as a major regulator of 
human blood pressure homeostasis and a contributor to the pathogenesis of 
hypertension. Environmental and internal stresses strongly stimulate 
adrenomedullary and sympathetic secretion of noradrenaline and 
adrenaline. The metabolic actions of these catecholamines mainly provide 
energy for immediate and effective responses in stress or emergency 
situations. They act as catalysts to mobilize free fatty acids from adipose 
tissue, and glucose and lactate from glycogen. Furthermore, they inhibit the 
secretion of insulin. Chiefly adrenaline induces glycogen breakdown in the 
liver and musculature, and promotes gluconeogenesis in the liver (Schmidt R 
1989). Both adrenaline and noradrenaline work as neurotransmitters as well 
as hormones (Schmidt R 1989). Noradrenaline (in US English 
norepinephrine) is the most common sympathetic postganglionic 
neurotransmitter, activating adrenergic receptors on the peripheral target 
organs or glands (Schmidt R 1989). 
 
Ghrelin 
Ghrelin is a peptide hormone, which apart from metabolic functions also 
influences the cardiovascular system. It has been shown to lower peripheral 
resistance, either directly at the vascular level and/or by centrally modulating 
sympathetic nervous system activity (Isgaard J 2011). Noradrenaline can 
stimulate ghrelin secretion, whereas insulin seems to inhibit it (Gagnon J 
2012). During pregnancy, decreased, unaltered, or increased plasma levels of 
ghrelin have been reported (Valsamakis G 2010).  
Ghrelin is a leptin inhibitor. Obesity-related hyperleptinaemia might 
increase central sympathetic nerve activity, which would lead to development 
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of hypertension, but the evidence is not conclusive (Lambert G 2010, 
Simonds S 2012, Machleidt F 2013). In animals leptin activates sympathetic 
nerve activity and in humans, serum leptin concentrations are closely 
correlated to muscle sympathetic nerve activity (MSNA) (Machleidt F 2013). 
Acute experimental hyperleptinaemia in humans has an excitatory effect on 
MSNA without changes in blood pressure, heart rate or plasma 
catecholamines (Machleidt F 2013). The role of leptin in chronically elevated 
sympathetic nerve activity, leading to hypertension, has not yet been shown 
(Simonds S 2012).  
 
Sympathetic activity and insulin resistance 
It is a well-known feature of insulin that it stimulates sympathetic nerve 
activity, particularly to skeletal muscle tissue (Grassi G 2004). Sympathetic 
over-activity and insulin resistance are linked in a positive-feedback fashion 
and two-way reinforcement, but which precedes the other is still unclear 
(Kaaja R 2006). 
 
Sympathetic over-activity and normal pregnancy 
In the first trimester of normal pregnancy during orthostatic stress the 
immediate heart rate increase provoked by standing up is unchanged, but the 
biphasic heart rate response is reduced, implying a diminished baroreflex-
induced slowing of the heart (Ekholm E 1996). In the third trimester the 
difference between standing and resting heart rate is found to be reduced or 
unchanged compared with early pregnancy, the post-partum period and the 
non-pregnant state (Ekholm E 1996). 
From the first trimester on, the immediate blood pressure reaction is also 
changed. On active standing up, systolic blood pressure rises during 
pregnancy instead of falling and diastolic blood pressure rises more in 
pregnancy than in the non-pregnant state (Ekholm E 1996). The blood 
pressure rise after standing up may be explained by increased sympathetic 
efferent activity to the blood vessels induced by the upright position, or a 
small decrease in stroke volume (Ekholm E 1996). 
Pregnancy does not affect the change in mean arterial pressure caused by 
standing up (Ekholm E 1996).  During orthostatic stress both systolic and 
diastolic blood pressure change in the same way in pregnant and non-
pregnant women (Ekholm E 1996). 
In the early weeks of normal pregnancy sympathetic activation in muscle 
seems to be enhanced compared with the non-pregnant state (Jarvis S 2012). 
In the 3rd trimester there is evidence of moderate sympathetic nervous 
system over-activity in muscle (MSNA) and in the heart as assessed by heart 
rate variability (HRV) analysis, but not in overall sympathetic activity as 
reflected in plasma noradrenaline levels (Kaaja R 2006). In HRV analysis the 
vagal component of the ANS seems to dominate in the 1st trimester of normal 
pregnancy and as pregnancy advances there is change towards greater 
sympathetic and lower vagal modulation (Kuo C 2000). 
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1.3.1 PIH AND SYMPATHETIC OVER-ACTIVITY 
There is evidence that second trimester diastolic, systolic, and/or mean 
arterial blood pressure can predict non-proteinuric PIH (Ekholm E 1994). 
Women with later PIH have been seen to lack the physiological drop in blood 
pressure in mid-pregnancy (Ekholm E 1994). 
In orthostatic tests in mid-pregnancy, heart rate and blood pressure 
reactions have been found not to differ in women with subsequent PIH 
compared with those remaining healthy (Ekholm E 1994). In women with 
proteinuric PIH, no differences have been found in heart rate and blood 
pressure responses compared with healthy pregnant women in the initial 
phase or in the steady state (Rang S 2002). 
In non-proteinuric PIH, direct recordings from peripheral sympathetic 
nerves have shown an increased sympathetic drive (MSNA) compared with 
that in normotensive non-pregnant women (Greenwood J 1998, Greenwood 
J 2001) and women with normal pregnancies (Greenwood J 2001, 
Greenwood J 2003). After delivery peripheral sympathetic hyperactivity 
seems to fall to normal in women with normal pregnancy and with non-
proteinuric PIH (Greenwood J 2001).  
Proteinuric pre-eclampsia has been recognized as a state of sympathetic 
over-activity - at least at the skeletal muscle level as demonstrated by MSNA 
(Schobel H 1996, Greenwood J 2003), in heart as demonstrated by HRV 
(Yang C 2000), and perhaps globally as reflected by increased venous 
noradrenaline (Manyonda I 1998) and by increased diurnal venous plasma 
levels of norepinephrine (Kaaja R 1999b). In pregnant women with pre-
eclampsia during a preceding pregnancy, pregnancy-induced sympathetic 
over-activity has been demonstrated by MSNA, which normalized after 
delivery (Fischer T 2004). However, it is not known whether women have 
increased sympathetic activity before the onset of pre-eclampsia. 
Compared with non-proteinuric PIH, sympathetic over-activity in muscle 
has not been found to be greater in proteinuric pre-eclampsia (Greenwood J 
2003). 
  
 31 
1.4 ANDROGENS 
Throughout normal pregnancy maternal total testosterone levels increase 
progressively (Bammann B 1980, O'Leary P 1991), whereas concentrations of 
dehydroepiandrosterone sulphate (DHEAS) decrease (O'Leary P 1991). 
Serum free testosterone concentrations barely change until the third 
trimester, when they increase about twofold (Bammann 1980). During 
pregnancy, circulating sex hormone-binding globulin (SHBG) concentrations 
are increased as a result of raised oestrogen levels (O'Leary P 1991), which 
might increase testosterone levels. Increased SHBG levels are expected to 
reduce, not increase, free testosterone levels. 
 
Androgens in hypertensive pregnancy 
Before clinical pre-eclampsia in the second trimester of pregnancy, maternal 
total testosterone levels (Carlsen S 2005) and free testosterone indexes 
(Carlsen S 2005) have been found to be elevated. In the third trimester 
maternal total testosterone levels (Carlsen S 2005, Salamalekis E 2006), the 
free testosterone index (Carlsen S 2005) and free testosterone levels 
(Salamalekis E 2006) were elevated in women with later pre-eclampsia 
compared with those who remained normotensive. However, first or second 
trimester concentrations of total testosterone, SHBG and the T/SHBG ratio 
have not been found to predict development of pre-eclampsia (Tuutti E 
2011). 
In most studies, during overt pre-eclampsia maternal total testosterone 
levels have been elevated compared with those in normotensive pregnancies 
(Acromite M 1999, Serin I 2001, Steier J 2002, Troisi R 2003, Atamer Y 
2004). In those studies where free testosterone was also determined, levels 
were higher in women with pre-eclampsia (Acromite M 1999, Serin I 2001). 
Maternal estradiol and DHEAS levels have been found to be the same in pre-
eclamptic and normotensive women (Acromite M 1999, Serin I 2001, Troisi 
R 2003, Atamer Y 2004).  
 
Relationship between androgens and insulin resistance 
It is well known that in women hyperinsulinaemia as a consequence of 
insulin resistance causes hyperandrogenaemia. Hyperinsulinaemia increases 
ovarian androgen production and decreases hepatic production of SHBG. 
Decreased SHBG levels lead to increased circulating concentrations of free 
testosterone. However, the metabolic consequences of androgen excess in 
women are not so clear, i.e. whether androgens adversely influence insulin 
action (Carbould A 2008) (Figure 2).  
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Figure 2 Hyperandrogenism and insulin resistance (adapted from Carbould A 2008) 
 
 
In women, androgen administration has been associated with the 
development of insulin resistance (Golden S 2004). In pre- and 
perimenopausal women a positive association has been found between the 
free androgen index (FAI) and insulin resistance (HOMA-IR), fasting insulin 
and glucose, even after adjustment for BMI (Sutton-Tyrell K 2005). In 
postmenopausal women the FAI has been associated with hyperinsulinaemia 
and hyperglycaemia (Golden S 2004) and bioavailable testosterone with 
insulin resistance (HOMA-IR) (Golden S 2007). In addition to direct effects 
of androgens on insulin action, androgens potentially influence insulin 
sensitivity in women indirectly through effects on lipid metabolism and body 
fat distribution, specifically as regards the development of central obesity 
(Arner P 2005, Pasquali R 2006, Corbould A 2008).  
 
Androgens in polycystic ovary syndrome (PCOS) 
Women with polycystic ovary syndrome (PCOS) are 3–4 times more likely to 
have non-proteinuric PIH and pre-eclampsia during pregnancy. They have 
been found to be at a higher risk of developing non-proteinuric PIH 
independently of BMI (Boomsma C 2006). Pregnant women with PCOS have 
higher androgen levels than their age-matched controls (Sir-Petermann T 
2002). In these women higher androgen levels might predispose them to pre-
eclampsia.  
It is well established that women with PCOS are at an increased risk of 
developing diabetes mellitus, glucose intolerance, hypertension, 
hyperlipidaemia (cardiovascular risk factors), metabolic syndrome and 
cardiovascular disease (Homburg R 2009). In women with PCOS, the 
prevalence of metabolic syndrome is high across all age groups (Essah P 
2006). In affected women, metabolic syndrome is particularly common in 
those with the highest insulin levels and a high BMI (Ehrmann D 2006).  
Hyperandrogenaemia may contribute to the increased risk of CVD in 
women with PCOS. In adolescent girls with PCOS, hyperandrogenaemia was 
found to be a significant predictor of metabolic syndrome independently of 
obesity and insulin resistance (Coviello A 2006). Even if hyperandrogenism 
partly resolves in women with PCOS before menopause, testosterone levels 
remain elevated compared with controls and this might increase their risk of 
Insulin resistance ↑Androgens
Hyperinsulinemia
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CVD (Winters S 2000, Legro R 2003). Augmented sympathetic nerve activity 
(MSNA) may contribute to the increased prevalence of CVD in PCOS 
(Sverrisdottir Y 2008). Serum testosterone concentrations are a strong 
predictor of sympathetic nerve activity in women with PCOS. The 
relationship between testosterone and the sympathetic nervous system is 
unclear (Sverrisdottir Y 2008).  
1.5 INFLAMMATION 
Normal pregnancy provokes an increased maternal systemic inflammatory 
response, at least in the third trimester (Sibai B 2005). In non-pregnant 
subjects, a subclinical elevation of high-sensitivity C-reactive protein (hs-
CRP) is a marker of systemic low-grade inflammation, and an efficient 
marker of cardiovascular events (Ridker P 2003). 
 
Inflammation in hypertensive pregnancy 
In pre-eclamptic pregnancy the inflammatory response is more extreme than 
in normal pregnancy (Sibai B 2005). In overt pre-eclampsia there are 
elevated levels of CRP (Teran E 2001), hs-CRP (Ertas I 2010), TNF-α and IL-
6 (LaMarca B 2007). Cytokines are thought to link placental ischaemia with 
cardiovascular and renal dysfunction. 
    In placental, renal, and vascular tissues TNF-α activates the endothelin 
system, and IL-6 stimulates the renin-angiotensin system (RAS) (LaMarca B 
2007). RAS and the sympathetic nervous system interact with 
proinflammatory cytokines. These cytokines affect angiogenic and 
endothelium-derived factors regulating endothelial function (LaMarca B 
2007). A novel candidate that induces TNF-α is a maternal autoantibody, the 
angiotensin II type I (AT(1)) receptor agonistic autoantibody (AA) (Irani R 
2010).  
 
Metabolic inflammation 
Inflammation is important in the causal pathway through which obesity 
predisposes women to pre-eclampsia (Wolf M 2001). Abnormal adipokine 
production and infiltration of inflammatory cells characterize dysfunctional 
adipose tissue. Visceral fat produces more CRP and inflammatory cytokines 
than subcutaneous fat, and contributes more to oxidative stress (Roberts J 
2011). 
    A form of metabolically driven, low-grade, chronic inflammation, 
“metaflammation” is associated with obesity and associated disorders such as 
insulin resistance and DM2 (Hotamisligil G 2006, Furuhashi M 2011). In the 
pathogenesis of chronic metabolic diseases such as DM2 and atherosclerosis, 
lipids and lipid signals are critical in integration of metabolic and 
inflammatory response systems (Hotamisligil G 2006). In addition to 
cytokines and lipids (extracellular mediators), intracellular stress 
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(endoplasmic reticulum stress and excess production of mitochondrial 
reactive oxygen species) can initiate metaflammatory pathways in 
metabolically active cells such as adipocytes and macrophages (Furuhashi M 
2011). The adipocytokine FABP4 integrates inflammatory and metabolic 
responses (Furuhashi M 2008). 
1.6 ANTI-ANGIOGENIC AND PRO-ANGIOGENIC 
FACTORS 
In pre-eclampsia placental stress stimulates release of several trophoblast-
derived factors that contribute to exaggerated maternal inflammatory 
responses. Inflammation and hypoxia up-regulate angiogenic factors 
initiating angiogenesis. Angiogenesis is induction and growth of new blood 
vessels from pre-existing ones. It is a complex, highly regulated system 
essential for growth of the foetus and placenta, wound healing and tumour 
development (Charnock-Jones D 2004).  
Circulating levels of placenta-derived anti-angiogenic proteins – soluble 
vascular endothelial growth factor receptor 1 (sVEGFR-1) or soluble fms-like 
tyrosine kinase-1 (sFlt1) and soluble endoglin (sEng) are increased before the 
onset of clinical pre-eclampsia (Levine R 2006). Circulating concentrations 
of pro-angiogenic factors such as free placental growth factor (PlGF) are 
reduced in pre-eclampsia (Levine R 2004, Staff A 2013). Higher levels of 
sFlt-1 are proposed to antagonize the vasodilatory effects of PlGF-1 and 
vascular endothelium-derived growth factor (VEGF), resulting in placental 
vascular insufficiency and other systemic effects (Solomon C 2006). It is 
implied that this angiogenic imbalance increases maternal vascular 
inflammation and generalized endothelial dysfunction (Staff A 2013). 
 
Angiopoietins and Tie receptors 
An important family of vascular endothelium-specific angiogenic growth 
factors are the angiopoietin (Ang) proteins. Most of them bind to endothelial 
cell-specific tyrosine kinase (Tie-2) receptors and are related to regulation of 
angiogenesis. Ang-1 and Ang-2 are produced by the villous trophoblast and 
are thought to play a substantial role in placental vascular development 
(Charnock-Jones D 2004, Seval Y 2008). Ang-1 activates and Ang-2 blocks 
Tie-2 receptors (Seval Y 2008). Circulating concentrations of Ang-1 are 
increased in (proteinuric) pre-eclampsia and non-proteinuric PIH (Nadar S 
2005), but not in the first trimester before later pre-eclampsia (Leinonen E 
2010). On the other hand, circulating concentrations of Ang-2 in the second 
trimester are increased in women with subsequent pre-eclampsia, but the 
levels seem to decrease from first trimester levels (Leinonen E 2010). During 
pre-eclampsia and non-proteinuric PIH, circulating concentrations of Ang-2 
are decreased (Nadar S 2005). In normal preganancy at least, maternal Ang-
1 and Ang-2 concentrations decrease rapidly after delivery (Keikkala E 2012). 
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Angiopoietin-like proteins 
Angiopoietin-like proteins (Angptls) or “angiopoietin-related proteins” 
(ARPs) are structurally similar to the angiopoietins: they contain a N-
terminal coiled-coil domain and a C-terminal fibrinogen-like domain, and a 
fibrinogen-like domain, and have angiogenic effects (Oike Y 2004). Angptls 
do not bind to either the angiopoietin receptor Tie-2 or the related protein 
Tie-1 (Oike Y 2004) and remain orphan ligands (Hato T 2008). The Angptl 
family has seven members (Angptl 1–7), which have been found in both 
humans and mice (Hato T 2008) (Table 4). Angptl1–4 and Angptl6 act on 
endothelial cells to control angiogenesis. Independently of their 
angiogenesis-regulating functions, Angptls3, 4 and 6 appear to directly 
regulate lipid, glucose and energy metabolism (Hato T 2008) (Table 4). 
Angptl2, 4 and 6 expression is up-regulated by a variety of factors, including 
hypoxia (Hato T 2008) (Table 4). 
Table 4. Biological effects of Angptls on angiogenesis and metabolism (adapted from 
Hato T 2008)  
 Angiogenesis Hypoxic induction Metabolism 
Angptl1 Pro/Anti No NR 
Angptl2 Pro Yes NR 
Angptl3 Pro No Inhibits LPL activity and 
increases serum TG levels 
Angptl4 Pro/Anti Yes Inhibits LPL activity and 
increases serum TG levels 
Angptl5 NR NR NR 
Angptl6 Pro Yes Increases energy expenditure 
Angptl7 NR NR NR 
NR no record; Pro, pro-angiogenic; Anti, anti-angiogenic; LPL, lipoprotein lipase; TG, 
triglyseride. 
1.6.1 ANGIOPOIETIN-LIKE PROTEIN 6 
Angiopoietin-like protein 6 (Angptl6) also called angiopoietin-related growth 
factor (AGF), is a liver-derived protein that independently of its pro-
angiogenic effect antagonizes the development of obesity and insulin 
resistance (insulin-sensitizing effect) and thereby tends to prevent the 
establishment of related metabolic diseases – at least in animal experiments 
(Oike Y 2005). Human studies indicate that circulating levels of Angptl6 are 
elevated in insulin-resistant states such obesity, diabetes (Ebert T 2009) and 
metabolic syndrome (Namkung J 2011). In animal experiments, Angptl6 
improves lipid profiles (Oike Y 2005), but it has no known effect on human 
lipoprotein metabolism (Miida T 2010). 
Like other pro-angiogenic factors including placental growth factor 
(Stepan H 2007), serum Angptl6 might be expected to be reduced in pre-
Hypertensive pregnancy 
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eclampsia, but in one study serum Angptl6 levels were elevated in pre-
eclamptic women compared with normotensive pregnant women (Stepan H 
2009), while in a recent study maternal Angptl levels were elevated in 
pregnant women compared with non-pregnant women, but there were no 
differences in pre-eclamptic and normotensive pregnant women (Xia G 
2013). 
1.7 LONG-TERM HEALTH CONCERNS 
1.7.1 INSULIN RESISTANCE 
Insulin resistance has been seen during PIH (Kaaja R 1999 a, Seely E 2003) 
and three months (Kaaja R 1999a) and 18 months after pre-eclamptic 
pregnancy (Wolf M 2004). However, in one study, five years after pre-
eclamptic pregnancy there were no differences in insulin sensitivity in 
women with previous pre-eclampsia and normotensive control women 
(Lampinen K 2008).  A history of (proteinuric) pre-eclampsia has been 
associated with mild hyperinsulinemia seventeen years after first pregnancy 
(Laivuori H 1996), but twenty years after pre-eclampsia a study group of 
women had only a tendency towards higher fasting insulin levels, but 
glycosylated haemoglobin levels were significantly higher than in controls 
(Sattar N 2003). Women with PIH have an increased risk of developing 
diabetes, even in the absence of GDM (Feig D 2013), but the presence of PIH 
and GDM raises the risk of diabetes significantly beyond that seen with GDM 
alone (Feig D 2013). 
Even without a history of hypertensive pregnancy, in women at or after 
menopause insulin resistance increases, and insulin secretion and 
elimination decrease (Kaaja R 2008 a). Decreased insulin sensitivity in the 
postmenopausal period has been thought to be due to oestrogen deficiency 
(Spencer C 1997). In women, advancing age and obesity also decrease insulin 
sensitivity (Guthrie J 2001, Carr M 2003). It is estimated that middle-aged 
women gain approximately 0.55 kg/year (Carr M 2003), as a result of 
increased abdominal obesity (Kaaja R 2008 a). Visceral fat increases with 
advancing age and after menopause decreased insulin sensitivity becomes 
significant as women get older (DeNino W 2001). More than menopausal 
status, an increase in body weight is likely to have a great influence on insulin 
sensitivity (Guthrie J 2001). Insulin resistance and increased visceral fat 
accumulation are two of the most important pathophysiological components 
of metabolic syndrome (Carr M 2003), but it is uncertain whether the 
starting point is insulin resistance leading to obesity, or vice versa (Kaaja R 
2008a). 
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1.7.2 SYMPATHETIC OVER-ACTIVITY 
In women with normal pregnancy and with non-proteinuric PIH, peripheral 
sympathetic hyperactivity seems to fall to normal after delivery (Greenwood 
J 2001). However, even in normotensive women with a history of pre-
eclampsia there are signs of increased sympathetic activity (Courtar D 2006). 
Five years after pre-eclampsia women have been found to have higher levels 
of noradrenaline compared with women with a history of normotensive 
pregnancy (Lampinen K 2014).  
Chronic activation of the sympathetic nervous system has been associated 
with components of metabolic syndrome such as blood pressure elevation 
(Esler M 2000), dyslipidaemia (Lambert E 2013), impaired fasting glucose 
with hyperinsulinaemia (Grassi G 2004) and obesity (Grassi G 1995, Esler M 
2001). A hyperactive sympathetic nervous system is clearly associated with 
metabolic syndrome (Brook R 2000, Grassi G 2005) and it seems that 
sympathetic hyperactivity is fundamental in the pathophysiology of the 
condition (Lambert G 2010) and might even precede insulin resistance 
(Lambert G 2010). Metabolic syndrome is a powerful risk factor of 
cardiovascular disease (McNeill A 2005) and CVD is also associated with a 
hyperactive sympathetic system (Thayer J 2010).  
1.7.3 ANDROGENS 
Even 17 years after pre-eclamptic pregnancy women have been found to have 
higher serum free testosterone concentrations and FAIs than controls 
(Laivuori H 1998). In women with pre-eclamptic pregnancy the higher levels 
of testosterone may contribute to the increased risk of later vascular 
morbidity. Cardiovascular disease is associated with endothelial dysfunction 
(Verma S 2002), like pre-eclampsia (Gilbert J 2008). In pregnant rats high 
androgen levels have been associated with endothelial dysfunction 
(Chinnathambi V 2013). To the best of my knowledge the literature on 
androgens in and after non-proteinuric PIH is scarce. 
1.7.4 METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE 
 
Pregnancy-induced hypertension and pre-eclampsia in particular, and CVD, 
share metabolic abnormalities: obesity, hypertension, insulin resistance and 
dyslipidaemia. Shared risk factors could explain the apparent association 
between pre-eclampsia and later CVD (Valdiviezo C 2012). These disorders 
also share common features of pathophysiology: oxidative stress, increased 
inflammatory activation, enhanced sympathetic activity and endothelial 
dysfunction. 
Five to six years after pre-eclampsia women have been found to have 
impaired endothelium-independent and endothelium-dependent 
Hypertensive pregnancy 
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vasodilatation (Lampinen K 2006). Endothelial dysfunction is associated 
with pre-eclampsia (Gilbert J 2008), atherosclerosis (Gimbrone M 1995) and 
CVD (Verma S 2002). An important risk factor of CVD is metabolic 
syndrome (Galassi A 2006). The first manifestation of metabolic syndrome 
may occur in pregnancy, presenting as pre-eclampsia or GDM (Kaaja R 2005, 
Kaaja R 2008b). Women with a history of PIH have an increased prevalence 
of metabolic syndrome as early as in their mid-30s (Forest J-C 2005). In 
women, PCOS (Essah P 2006) and visceral obesity increase the risk of 
metabolic syndrome (Carr M 2003).  
Metabolic syndrome is a term describing a cluster of metabolically related 
cardiovascular risk factors (Alberti K 2006). Insulin resistance, hypertension, 
dyslipidaemia (increased triglyceride and decreased HDL levels) and obesity 
characterize the syndrome. Although obesity seems to be strongly related to 
metabolic syndrome, not all obese subjects develop the condition. The 
clinical criteria of metabolic syndrome as defined by the International 
Diabetes Federation (IDF) (Alberti K 2006), the World Health Organisation 
(World Health Organisation 1999) and the National Cholesterol Education 
Program Adult Treatment Panel-III (ATP III) (Expert Panel 2001) are given 
in Table 5. In Study III we used IDF diagnostic criteria (Alberti K 2006) for 
diagnosis of metabolic syndrome. In IDF criteria abdominal obesity and two 
additional factors are sufficient for the diagnosis. 
 
The prevalence of metabolic syndrome increases with age, especially after 
menopause (Kaaja R 2008a). Menopause itself has many characteristics of 
metabolic syndrome (Spencer C 1997). Metabolic syndrome could be the 
possible underlying mechanism common to pre-eclampsia and CVD. 
Regardless of their proteinuric status (Männistö T 2013), women with 
hypertensive pregnancies are at increased risk of later cardiovascular disease 
and mortality (Bellamy L 2007, Valdiviezo C 2012). Women with a history of 
pre-eclampsia have a 3- to 4-fold increased risk of developing hypertension, a 
twofold increased risk of ischaemic heart disease and an increased stroke risk 
compared with women without such a history (Valdiviezo C 2012). Women 
with prior pre-eclampsia, especially those with early onset disease (≤ 37 
weeks of gestation) (Bellamy L 2007) and recurring disease in subsequent 
pregnancies (Lykke J 2009), carry an enhanced risk of future CVD. The risk 
of future cardiovascular events increases significantly if pregnancy has been 
complicated by both hypertensive disorders of pregnancy and GDM (Sullivan 
S 2011). 
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Table 5. Clinical criteria defining metabolic syndrome in women 
 IDF  World Health 
Organisation 
Definition 
ATP III Definition  
Reference (Alberti K 2006) (WHO 1999) (Expert Panel 2001) 
Needed for diagnosis Central obesity plus 
any two of the four 
additional factors 
Fasting 
hyperinsulinaemia 
or impaired 
glucoregulation and 
> 2 other factors 
≥ 3 of 5 risk factors 
Central obesity    
Waist circumference 
 
≥ 80 cm for Europid 
women 
 > 88 cm for women 
WHR  > 0.85 for women 
and/or  
 
BMI  BMI > 30 kg/m2  
Glucose tolerance    
Fasting plasma 
glucose 
≥ 5.6 mmol/l and/or ≥ 6.1 mmol/l ≥ 6.1 mmol/l 
Previously diagnosed 
type 2 diabetes 
Yes   
Blood pressure    
Systolic ≥ 130 mmHg and/or ≥ 140 mmHg and ≥ 130 mmHg and/or 
Diastolic ≥ 85 mmHg and/or > 90 mmHg ≥ 85 mmHg 
Treatment of 
previously diagnosed 
hypertension 
Yes    
Dyslipidaemia    
Triglycerides ≥ 1.7 mmol/l, or 
specific treatment for 
this lipid abnormality 
≥ 1.7 mmol/l for 
women 
> 1.69 mmol/l 
HDL cholesterol < 1.29 mmol/l in 
females, or specific 
treatment for this lipid 
abnormality 
< 1.0 mmol/l for 
women 
< 1.29 mmol/l for 
women 
Microalbuminuria Not included in criteria ≥ 20 mg/min or 
albumin/creatinine 
≥ 30 mg/g 
Not included in 
criteria 
ATP III, Adult Treatment Panel-III; WHR, waist-to-hip ratio; HDL. high-density lipoprotein. 
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2 MEASUREMENT OF INSULIN 
SENSITIVITY 
All the used techniques to estimate insulin sensitivity in vivo during 
pregnancy have limitations. During pregnancy, there is non-insulin-mediated 
glucose disposal from the mother to the foetus through placentally facilitated 
diffusion of glucose. Therefore, all estimates of insulin sensitivity in 
pregnancy are overestimates of maternal insulin sensitivity, particularly in 
late gestation (Catalano P 2010). 
 
The hyperinsulinaemic-euglycaemic clamp 
The gold standard method in measuring insulin sensitivity is the 
hyperinsulinaemic euglycaemic clamp (DeFronzo R 1985, Kaaja R 2006, 
Catalano P 2010), but it is an invasive method mainly used for research 
purposes when accuracy and reproducibility of the measures are required 
(Kaaja R 2006, Catalano P 2010). 
In this technique, insulin is infused in order to attain a steady-state 
insulin concentration. A variable glucose infusion is then used, based on 
frequent glucose sampling, in order to maintain a constant euglycaemic 
glucose concentration, i.e. the glucose is clamped at a steady-state level 
(DeFronzo R 1985, Catalano P 2010). 
 
Minimal model analysis of the intravenous glucose tolerance test 
(IGTT) 
Like the hyperinsulinaemic-euglycaemic clamp, minimal model analysis of 
the intravenous glucose tolerance test (IGTT) is an invasive method mainly 
used for research purposes (Bergman R 1987). Insulin sensitivity is 
estimated, but it may be less useful in late gestation when insulin sensitivity 
is decreased, compared with the euglycaemic clamp, because of the increased 
variability in insulin sensitivity estimation (Catalano P 2010). 
 
Insulin sensitivity indexes (ISIs) 
Fasting glucose and insulin characterize only the insulin sensitivity of the 
liver (Abdul-Ghani M 2007). Insulin sensitivity indexes are more common 
clinical methods used to estimate insulin sensitivity. A quantitative insulin 
sensitivity check index (QUICKI) (Katz A 2000) and a homeostatic 
assessment model (HOMA) (Matthews D 1985) are insulin sensitivity 
indexes calculated by using fasting concentrations of plasma glucose and 
insulin. These indexes have been shown to be good predictors of insulin 
sensitivity in subjects with normal glucose tolerance and diabetes, but they 
are inaccurate in patients with impaired glucose tolerance or a new stage of 
non-diabetic impaired fasting hyperglycaemia (Kaaja R 2006), since at pre-
diabetic stages insulin levels may be elevated. Indices involving fasting 
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concentrations of glucose and insulin primarily reflect hepatic insulin 
sensitivity, but not insulin action in peripheral tissue (Kaaja R 2006, Abdul-
Ghani M 2007).  
To evaluate whole-body glucose tolerance in vivo, the most commonly 
used method is the oral glucose tolerance test (OGTT). The Matsuda and 
DeFronzo insulin sensitivity index (ISI) is calculated from the 75-g 2-h OGTT 
(Matsuda M 1999). Matsuda ISIs correlate well (r = 0.73, p < 0.0001) with 
ISIs derived from the euglycaemic clamp technique (Matsuda M 1999).  
The products of the area under the plasma glucose curve and under the 
plasma insulin curve have been used as an index of insulin resistance, but the 
concept has not been validated (Matsuda M 1999). 
Measurement of sympathetic activity 
42 
3 MEASUREMENT OF SYMPATHETIC 
ACTIVITY 
Assessment of the autonomic nervous system 
Autonomic nervous control can be non-invasively studied by analysis of 
spontaneous heart rate and blood pressure variability from continuous 
recordings of heart rate and blood pressure, or by analysing blood pressure 
and heart rate responses to a variety of physiological stresses in 
cardiovascular reflex tests, such as the Valsalva manoeuvre, the orthostatic 
stress test, the isometric handgrip test and by measuring heart rate 
variability (Ekholm E 1996, Rang S 2002). During pregnancy non-invasive 
methods are especially of interest, since they carry minimal risks to the 
mother and foetus and can be used repeatedly (Rang S 2002). The 
limitations of these non-invasive tests are that they do not reveal the level of 
disturbed autonomic regulation of blood pressure and most non-invasive test 
methods show large inter-individual variability (Rang S 2002).  
 
Orthostatic stress test 
In the orthostatic stress test one changes posture rapidly from lying to an 
upright position, remaining standing still for a desired time (in our study 10 
minutes). Blood pressure and heart rate are measured at different time 
points.  
In normal subjects, when posture is changed from supine to upright it causes 
blood to pool from the thorax into the veins of the lower extremities and 
trigger reflex changes characterized by sympathetic activation, vagal 
withdrawal and release of renin and vasopressin (Chen G-Y 1999).  
Usually, in non-pregnant persons, moving from a supine to a standing 
position results in a transient drop in systolic blood pressure (≤ 20 mmHg) 
and a rise in heart rate (≤ 20 beats/min) (Thulesius O 1976). However, the 
heart rate response is biphasic and within 30 s after standing up the 
increased heart rate is followed by a rapid decrease (Ekholm E 1996), 
stabilized by the end of 3 minutes. An upright position primarily amplifies 
the sympathetic noradrenergic system of the heart and peripheral blood 
vessels. The aggravated tachycardia as a reaction to standing up suggests an 
increased sympathetic outflow to the heart. In the orthostatic test the blood 
pressure and heart rate differences between supine and upright positions are 
related to plasma noradrenaline levels (Ewing D 1985). 
In normal subjects, compared with the supine position, assuming the 
right- or left-lateral decubitus position demonstrates higher vagal and lower 
sympathetic modulation (Kuo C 2000). 
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Heart rate variability (HRV) 
Heart rate has been proposed as a global index of ANS influence on the heart, 
and an elevated heart rate may reflect a shift in the autonomic balance 
toward enhanced sympathetic and suppressed vagal tone. Elevated heart rate 
has been predictive of cardiovascular disease (Festa A 2000).  
 
Time domain method 
Perhaps the simplest way to measure heart rate variation is a time domain 
method of assessing heart rate variability (HRV). With these methods either 
the heart rate at any point in time or the intervals between successive normal 
complexes are determined (Eur Heart J 1996). 
 
Frequency domain method 
A power spectral analysis of variation in heart rate is one of the frequency 
domain methods of assessing HRV. It is based on mathematical models to 
determine the balance between sympathetic and vagal nerve activities in the 
heart (Kaaja R 2006). Power spectral analysis of variation is a dynamic and 
non-invasive technique, but it seems to have poor correlation with 
noradrenaline spillover from the heart and nerve firing rates determined by 
microneurography in situations where stimuli other than arterial and low-
pressure baroreceptors (postural stimulation) are engaged (Kaaja R 2006).  
 
Measurement of sympathetic activity 
Sympathetic drive in humans can be measured by 1) assay of plasma and 
urinary catecholamines (noradrenaline and adrenalin), 2) assessment of 
systemic and regional noradrenaline spillover, and 3) direct sympathetic 
nerve recordings. However, there is no “gold standard” technique to assess 
sympathetic activity (Grassi G 1999, Kaaja R 2006). Various techniques are 
complementary. 
 
Muscle sympathetic nerve activity (MSNA)  
So far, in humans the only method for direct recording of regional 
sympathetic nerve traffic is muscle sympathetic nerve activity (MSNA) 
measured via microneurography. In MSNA efferent postganglionic muscle 
sympathetic nerve activity is assessed (from peroneal or brachial nerves) 
(Grassi G 1999). Direct recordings allow discrimination between the central 
or peripheral nature of increased plasma noradrenaline levels, and precise 
estimation of the behaviour of regional sympathetic neural function both 
under physiological and pathological conditions (Grassi G 1999). The rise in 
MSNA is a direct measure of central (baroreceptor reflex-controlled) 
sympathetic vasoconstrictor impulses to the muscle vascular bed. An 
important limitation in clinical research is that the method is invasive and 
there is inaccessibility to the sympathetic nerves to internal organs. In this 
regard an indirect inference of sympathetic activity from regional 
noradrenaline spillover measurements is more helpful. 
Measurement of sympathetic activity 
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Regional and systemic noradrenaline spillover 
A release of sympathetic neurotransmitter to plasma from an individual 
organ is regional spillover, which is studied using the principal of isotope 
dilution, with intravenous infusion of tritiated noradrenaline and sampling 
from venous drainage of the organ in question (mainly heart and kidney). 
The whole body noradrenaline spillover rate gives a measure of overall 
sympathetic nervous activity (Grassi G 1999). Spillover methods with 
radioactive agents are contraindicated during pregnancy.  
 
Plasma noradrenaline 
 Measurement of plasma noradrenaline concentration in venous blood is the 
most commonly employed index of sympathetic activity in man, but it is 
relatively insensitive (Grassi G 1999). Most of the noradrenaline secreted 
from the sympathetic fibres is destroyed or taken up again and only a minute 
fraction escapes from the neuroeffector junctions (Grassi G 1995). The 
sympathetic nervous system typically shows regional differentiation, so that 
sympathetic outflow to some organs may be activated while that to other 
regions may be unchanged or inhibited (Grassi G 1999). The plasma 
noradrenaline concentration gives no indication of the source of the hormone 
and does not discriminate between central (increased secretion) and 
peripheral (decreased clearance) mechanisms of augmentation (Grassi G 
1999, Kaaja R 2006). Furthermore, venous noradrenaline assays have shown 
limited reproducibility, and sensitivity in detecting increased sympathetic 
nerve activity is not optimal (Grassi G 1999, Kaaja R 2006). Plasma 
noradrenaline has a diurnal rhythm and high-performance liquid 
chromatography (HPLC) is used to measure diurnal plasma noradrenaline 
levels (Kaaja R 1999b).  
 
Plasma adrenaline 
The adrenal medulla acts as a modified sympathetic ganglion and adrenal 
neurons directly release catecholamines (noradrenaline and adrenaline) into 
the blood stream, mainly adrenaline. Therefore, plasma adrenaline levels 
mainly reflect adrenal medulla production of the hormone (Schmidt R 1989) 
and they are generally taken as a valid index of adrenal medullar production 
of the hormone. 
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4 AIMS OF THE STUDY 
To seek associations between maternal serum FABP4 levels in the second 
and third trimesters of pregnancy and indices of possible insulin resistance, 
sympathetic over-activity, inflammation and hyperandrogenism in cases of 
PIH (I).  
 
To assess if maternal serum levels of Angptl6 and FABP4 in the second 
trimester of pregnancy are associated with subsequent development of 
hypertensive pregnancy and indices of possible insulin resistance, 
sympathetic over-activity, inflammation and hyperandrogenism in cases of 
PIH (II). 
 
To evaluate sympathetic activity by way of neurohormonal indices in pre-
eclamptic pregnancy in connection with different body postures (III). 
 
To assess diurnal glucose profiles in cases of GDM with and without 
hypertensive complications (IV). 
 
To assess if there are signs of insulin resistance and hyperandrogenism in the 
premenopausal period in women with a history of pre-eclampsia (V). 
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5 SUBJECTS AND METHODS 
All five studies were approved by the Ethics Committee of the Department of 
Obstetrics and Gynaecology, Helsinki University Central Hospital (HUCH). 
The approval number for Study III is 296/E8/2000 and that for Studies IV 
and V, 045/97. All women gave informed consent except in Study I, where a 
standard clinical procedure was followed and therefore no patient consent 
was needed. 
5.1 WOMEN WITH SUBSEQUENT PIH (I, II) 
Studies I and II were prospective observational studies. In Study I 72 
women and in Study II a subset of 47 women were investigated. They were at 
a relatively high risk of developing pre-eclampsia, because of relative 
overweight (BMI ≥ 24 kg/m2) and nulliparity (Figure 3). All women had a 
singleton pregnancy. Women were recruited from consecutive referrals for a 
routine first-trimester ultrasonographic scan at Helsinki University Central 
Hospital maternal policlinic.  
All women underwent the same study protocol at a single site (Table 6), 
and also underwent routine maternity ward follow-up. The first examination 
was at 24 weeks of gestation and the study included 106 women. Table 6 
shows detailed information of the orthostatic test, a standard 2-hour 75-g 
OGTT, and laboratory analysis at 24 and 32 weeks of gestation. At baseline, a 
venous sample was drawn from an antecubital vein after at least 12 hours 
fasting. Mean arterial pressure (MAP) was calculated as ([2 × DBP] + 
SBP)/3. Delta systolic BP (ΔSBP) was calculated as SBP after standing minus 
SBP after rest. Insulin resistance was estimated by using the whole-body 
insulin sensitivity index (ISI) (Matsuda M 1999) and the homeostatic model 
assessment – insulin resistance (HOMA-IR) (Matthews D 1985) at 24 weeks 
of gestation. The Matsuda whole-body ISI was calculated as follows: 10 000 
/√ ([fasting plasma glucose × fasting serum insulin] × [mean OGTT glucose 
concentration × mean OGTT insulin concentration]) (Matsuda M 1999). 
HOMA-IR was calculated as follows: (G0 × I0)/22.5, where G0 is fasting 
glucose (mmol/l) and I0 is fasting insulin (μU/ml) (Matthews D 1985). The 
first trimester of pregnancy was defined as ≤ 13 w + 2 d of gestation and the 
second trimester as ≤ 26 w + 4 d of gestation. 
Diagnoses of non-proteinuric PIH and proteinuric PIH (pre-eclampsia) 
were based on criteria of the National High Blood Pressure Education 
Program Working Group on High Blood Pressure in Pregnancy (National 
2000) (Table 1). PIH was defined as systolic BP (SBP) elevation to ≥ 140 
mmHg or diastolic BP (DBP) elevation to ≥ 90 mmHg after 20 weeks of 
gestation with (pre-eclampsia) or without proteinuria. Proteinuria was 
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defined as ≥ 0.3 g protein/24 hours or ≥ 1+ in dipstick testing. Pre-eclampsia 
was regarded as serious if severe hypertension was associated with 
proteinuria or if hypertension was associated with severe proteinuria (≥ 5 g 
per day). Hypertension was regarded as severe if SBP was sustained at ≥ 160 
mmHg or DBP sustained at ≥ 110 mmHg, or both (Sibai B 2005). Chronic 
hypertension was diagnosed as SBP elevation to ≥ 140 mmHg or DBP 
elevation to ≥ 90 mmHg, or both, repeatedly before 20 weeks of gestation. 
Normotensive women had normal BP (< 140/90 mmHg) and no proteinuria 
during pregnancy. 
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Figure 3 Flow chart concerning research subjects in Studies I and II 
 
 
Excluded n=34
Study  women
n = 106 
Proteinuric PIH 
(pre-eclampsia)
n = 12
Non-proteinuric 
PIH
n = 14
Norm otensives 
n = 46 
Angptl6 
m easurements 
n = 47
Proteinuric PIH 
(pre-eclampsia)
n = 12
Non-proteinuric
PIH
n = 12
Norm otensives b)
n = 23
Included :
No prior pregnancies of  ≥ 20 gw
Pre-pregnancy BMI ≥ 24 kg/m2
Blood pressure < 140/90 mmHg and
absent proteinuria by dipstick
No major health problems
n = 8 chronic hypertension 
n = 6 pre-existing disorders
n = 1 4 inadequate patient notes labor ward
records or lost from the study 
n = 2 a pre-pregnancy BMI < 24 kg/m2
n = 1  underwent assisted reproduction  
n = 3  no serum available for FABP4 measurements a)
a) For 1  woman with proteinuric PIH and 2 normotensive women.
b) Angptl6 measurements were made only in a subset of normotensives and 1 outlier was excluded.
After Angptl6 measurements patient notes were supplemented for one woman with non -proteinuric PIH and 4 
normotensives and diagnoses were  supplemented for one woman with proteinuric PIH and 2 women with non -proteinuric 
PIH (1  woman with subsequent non-proteinuric PIH was among those whose patient notes were supplemented).
Early onset (<34 gw) PE n=0
Late onset (≥  34 gw) PE n=12
Sev ere PE n=3
Mild PE n=9
FABP4
m easurements 
n = 7 2
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5.2 WOMEN DURING PRE-ECLAMPSIA (III) 
Study III was a case-control study of 36 women with: pre-eclampsia (n=11) 
studied at 37 gestational weeks, normotensive pregnancy (n=17) studied at 
38 gestational weeks, and non-pregnant controls (n=8). Patients with signs 
of foetal distress, severe pre-eclampsia (BP ≥ 170/110 mmHg, proteinuria ≥ 5 
g/24 h), severe intrauterine growth retardation, diabetes, secondary 
hypertension or medication were excluded. Of the 36 study women, 6 pre-
eclamptic and 9 normotensive pregnant women were studied at Helsinki 
University Hospital, Finland, while the others were studied at Christchurch 
Hospital, New Zealand.  
Measurements of arterial pressure, heart rate and neurohormones were 
carried out with subjects in the left-lateral position, then supine, left-lateral, 
in an upright posture and the left-lateral position again. The measured 
neurohormones were: noradrenaline, adrenaline, renin activity, natriuretic 
peptides and endothelin-1. Blood pressure status was classified as 
recommended by the National High Blood Pressure Education Program 
Working Group on High Blood Pressure in Pregnancy report in 1990 
(National 1990).  
5.3 WOMEN WITH GDM (IV) 
Study IV was a prospective follow-up study of 178 women with gestational 
diabetes, who delivered at the Department of Obstetrics and Gynaecology, 
HUCH, over 1 year (January 1, 1995 to December 31, 1995). In the same time 
period the total number of deliveries at HUCH was 5343.  
The diagnosis of gestational diabetes was based on 75-g 2-h OGTTs, 
carried out at 28–32 weeks of gestation among pregnant women with one or 
more of the following risk factors of GDM: glucosuria, obesity (BMI ≥ 25 
kg/m2), previous delivery of a macrosomic infant (≥ 4500 g), previous GDM, 
maternal age ≥ 40, estimated foetal weight ≥ 2 SD units in current 
pregnancy. At that time normal upper limits for capillary blood or venous 
plasma glucose values were: fasting 4.8 mmol/l, 1-h 10.0 mmol/l, and 2-h 8.7 
mmol/l (Hyvönen K 1991).  
Glucose intolerance suggested by OGTT results was confirmed usually 
within 2 weeks with a blood glucose profile, measuring blood glucose every 4 
h over 24 h. Five measurements were fasting/pre-prandial (08.00, 16.00, 
00.00, 04.00, 08.00 h) and two were post-prandial (1 h after meal) at 12.00 
and 20.00 h. After 24-h glucose profiles, of the 178 women with GDM, 55 
were started on insulin treatment (White A/B) and 123 women had only 
dietetic treatment (White A). 
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Women were classified as being normotensive (n = 102), having chronic 
hypertension (n = 42) (with or without superimposed pre-eclampsia on 
chronic hypertension) or PIH (n = 34) (with or without proteinuria) 
(National 1990).  
 Diurnal blood glucose profiles were compared in these groups. Changes 
in blood glucose levels were also calculated in obese (BMI ≥ 28 kg/m2) and 
non-obese women (BMI < 28 kg/m2), regardless of hypertension. 
5.4 WOMEN IN THE PERIMENOPAUSAL PERIOD (V) 
Study V was a case-control study of 18 women with a history of pre-eclamptic 
first pregnancy and 19 women with prior normotensive first pregnancy 
studied 23–24 years after delivery (Table 7). Both the study women and the 
controls had delivered at the Department of Obstetrics and Gynaecology, 
Helsinki University Hospital, Finland, from the 16th of March 1975 to the 4th 
of January 1980, and were all Caucasian. 
 
Table 7. Subjects in Study V 
Study group No of 
subjects 
Inclusion criteria Exclusion criteria 
A history of pre-
eclamptic 
pregnancy 
18 Pre-eclampsia during index 
pregnancy 
? Pre-existing medical 
disorders before index 
pregnancy 
? Assisted reproductive 
techniques 
? Multiple pregnancies 
? Hormone replacement 
therapy a) 
Prior 
normotensive 
pregnancy 
19 Normal blood pressure and 
no proteinuria during index 
pregnancy 
GDM; gestational diabetes mellitus, PIH; pregnancy-induced hypertension, OGTT; oral 
glucose tolerance test 
a) Oestrogen substitution and contraceptive pills increase SHBG levels and inhibit 
testosterone production thorough LH suppression. 
 
The diagnosis of proteinuric PIH (pre-eclampsia) was based on criteria of 
the National High Blood Pressure Education Program Working Group on 
High Blood Pressure in Pregnancy (National 2000) (Table 1). 75-g 2-h 
OGTTs were carried out and Matsuda´s whole-body insulin sensitivity index 
(Matsuda ISI) was calculated. Based on a 75-g 2-h OGTT, glucose tolerance 
was categorized to normal, diabetes, and abnormal glucose tolerance 
according to American Diabetes Association criteria (The Expert Committee 
2003) (Table 8). Abnormal glucose tolerance included both impaired fasting 
glucose and impaired glucose tolerance. In 2-hour OGTTs, plasma glucose 
was assessed at 0, 1 and 2 hours after a 75-g oral glucose load.  
Subjects and methods 
52 
Table 8. Glucose tolerance evaluated via 2-hour 75-g OGTTs according to American 
Diabetes Association criteria (Expert committee 2003) 
 Normal Abnormal glucose tolerance Diabetes 
fP-gluc < 6.1 mmol/l 6.1 – 6.9 mmol/l ≥ 7.0 mmol/l 
 and and/or and/or 
2-hour P-gluc < 7.8 mmol/l 7.8 – 11.0 mmol/l ≥ 11.1 mmol/l 
 
Areas under the curve (AUCs) were calculated for glucose and insulin. 
Glucose AUCs (mmol/l * minutes) at 120 min were evaluated according to 
the formula 15* (G0 + 2*G30 + 3*G60 + 2*G120), where G is a glucose value 
at each time point, and insulin AUCs (μU/ml * minutes) at 120 min were 
evaluated according to the formula 30* (I0 + 2*I60 + I120), where I is a 
insulin value at each time point (Matthews J 1990). 
 
Serum concentrations of follicle-stimulating hormone (FSH), sex 
hormone-binding globulin (SHBG), total and calculated free testosterone, 
dehydroepiandrosterone sulphate (DHEAS), luteinizing hormone (LH), total 
cholesterol, high-density lipoprotein (HDL) cholesterol, hormone-sensitive 
high-density lipoprotein (HDL2) cholesterol, HDL3 cholesterol, triglycerides, 
low-density lipoprotein (LDL) cholesterol and plasma insulin were assessed. 
Diagnoses of metabolic syndrome were based on IDF criteria (Alberti K 
2006) (Table 5). A PCOS phenotype was defined using the Rotterdam 
ESHRE/ASRM-Sponsored PCOS Consensus Workshop Croup (2004) criteria 
as the presence of two or more of the following features: (1) history of 
oligomenorrhoea/amenorrhoea, (2) clinical and/or biochemical signs of 
hyperandrogenism (hirsutism, acne and/or S-testosterone > 2.7 nmol/l) and 
(3) polycystic ovaries detected in ultrasonography (Rotterdam 2004). 
5.5 BLOOD SAMPLE ANALYSES 
Venous blood samples were drawn into heparinized (serum) tubes and EDTA 
(plasma) tubes on ice, centrifuged for 10 min and the samples stored at -20 
or -80 ºC until analysis.  
 
Adrenaline, noradrenaline and ghrelin 
For measurements of adrenaline, noradrenaline (Eisenhofer G 1986) and 
ghrelin (Davis M 2004) plasma was transported on ice to Endolab, 
Christchurch Hospital in New Zealand. All individual samples were analysed 
in a single assay. The intra-assay coefficients of variation for these assays 
varied between 2.4% (for noradrenaline) and 8.3% (for ghrelin) (I, II). The 
intra-assay coefficient of variation for noradrenaline in Study II was 6%. 
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Angiopoietin-like protein 6 (Angptl6)  
Serum Angptl6 concentrations were analysed using a commercial ELISA 
method according to the protocol described in the package insert (Adipogen 
ANGPLT6 Human ELISA Kit, TwinPlex, Cat. no. AG-45A-0016TP-Kio1). 
Validation of the Angptl-6 ELISA assay was based in part on the use of 
quality control samples included in each ELISA kit. The expected range ± SD 
for Angptl6 in the quality control sample was 20 ± 5 ng/ml. The mean value 
of this sample in our assay was 22.9 ng/ml with intra- and inter-assay 
precision values (coefficients of variation) of 1.2% and 2.4%, respectively. 
The standard curves for the ELISA assays, i.e. Angptl6 concentrations plotted 
against absorbance values showed good stability and reproducibility (r = 
0.983 ± 0.01 (SD)). 
 
Fatty acid binding protein 4 (FABP4)  
Serum FABP4 concentrations were analysed by using a non-competitive 
ELISA (Biovendor RD 191036200R). Intra- and inter-assay variations were 
about 2.5% and 5.5%, respectively. The manufacturer reports a normal range 
of 19.6 ± 8.1 ng/ml (mean ± 1 SD) for 35- to 52-year-old women. 
 
Follicle-stimulating hormone (FSH) and luteinizing hormone 
(LH) 
Serum concentrations of FSH and LH were determined by time-resolved 
immunofluorometric assays from Perkin-Elmer, Wallace Ltd. (AutoDelfia, 
Turku, Finland). 
 
High sensitivity CRP (hs-CRP)  
A high-sensitivity CRP (hs-CRP) assay measures low plasma levels of CRP.  
Hs-CRP was measured by particle-enhanced immunoturbidimetric assay 
(CRP (Latex) HS, Tina-quant C-reactive protein (latex) high sensitivity assay, 
Roche Diagnostics) on a Modular automatic analyzer (Hitachi Ltd., Tokyo, 
Japan). The intra-assay coefficients of variation (CVs) were 1.1% at 0.70 mg/l 
and 0.7% at 5.9 mg/l and the inter-assay CVs were 8.2% at 0.44 mg/l (n=81) 
and 3.3% at 2.94 mg/l (n= 81). The method is accredited by FINAS 
Accreditation (SFS-EN ISO/IEC 17025:2005 and SFS-EN ISO 15189:2007). 
 
Lipids  
Total cholesterol and total HDL cholesterol concentrations were measured by 
using commercial kits (Boehringer, Mannheim, Germany). Triglyceride 
concentrations were analysed in a Technicon autoanalyzer (AutoAnalyzer II; 
Technicon Instruments, Tarrytown, NY). For hormone-sensitive high-density 
lipoprotein cholesterol (HDL2 cholesterol) and HDL3 cholesterol analysis, 
HDL cholesterol was separated from serum by precipitation of the other 
lipoproteins with heparin-manganese chloride (Gidez L 1982). The 
supernatant was further fractioned into HDL2 and HDL3 cholesterol by 
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precipitation with 0.11% dextran sulphate. Concentrations of LDL cholesterol 
were calculated by using the Friedewald equation (Friedewald W 1972).  
 
Total serum testosterone  
In Study I serum testosterone concentrations were measured by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). Before analysis, 
30 μl of 0.2 μM deuterated testosterone as internal standard (IS) (D3-
testosterone, Sigma) in 50% (vol./vol.) methanol was added to 250 μl of 
serum before extraction with 4 ml of diethyl ether. After mixing for 3 min 
and centrifugation the upper layer was collected and evaporated to dryness 
under nitrogen. The residue was dissolved in 250 μl of 50% methanol. 
Calibrators containing 0.2–100 nM testosterone (Fluka) were prepared in 
50% methanol. Twenty-five μl of sample extracts and calibrators were 
analysed on an LC-MS/MS system equipped with an API 2000 triple 
quadrupole mass spectrometer (PE Sciex, Foster City, CA). Peripherals 
included an Agilent series 1200 high-performance liquid chromatography 
system with a binary pump (Waldbronn, Germany). Separation was 
performed on a SunFire C18 column (2.1 × 50 mm; Waters, Milford, MA). 
The mobile phase was a linear gradient consisting of methanol and 130 μM 
ammonium acetate in water, at a flow rate of 250 μl/min. The gradient was: 
0 min, 50% methanol; 2 min 95% methanol; 3 min 95% methanol; and 3.5–
10 min 50% methanol. The column was directly connected to the 
electrospray ionization probe. Testosterone was detected as protonated ions 
in the positive mode with the following transitions: m/z 289 to m/z 97 & 109 
and IS, m/z 292 to m/z 97. Data were acquired and processed via Analyst 
Software (Ver 1.4; Sciex). Mass calibration and resolution adjustments (at 0.7 
atomic mass units at full width and half height) on both the resolving 
quadrupoles were optimised using a polypropylene glycol solution with an 
infusion pump. 
In Study V, for measurements of total testosterone we used a specific liquid 
chromatography-tandem mass spectrometric method (LC-MS/MS) with an 
API 2000 triple quadrupole mass spectrometer (PE Sciex, Foster City, CA, 
USA) and deuterated testosterone as an internal standard (Turpeinen U 
2008).  
 
Calculated androgen indexes (I, V) 
Free, non-protein bound, calculated free testosterone (cfT) (I, V) was 
calculated by using an equation published by Anderson et al.: 100 * S-Testo * 
(testo-V%) = 10 * S-Testo * (2.28 – 1.38χ * log[S-SHBG/10]) (Andersson D 
1975). In Study III we used the following formula to calculate the free 
androgen index (FAI): 100 * S-Testo (ng/dl)/28.84 * S-SHBG (nmol/l) 
(Sutton-Tyrell K 2005). 
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5.6 STATISTICAL METHODS 
Statistical analyses were performed by using an NCSS 2000 statistical 
package (NCSS, Inc., Kaysville, UT, USA), except in Study III. Table 10 shows 
the statistical analyses used in the studies.  
Table 10. Statistical analyses used in the studies. 
Analysis Study 
Descriptive statistics I–V 
Power calculations V 
Analysis of distribution  
? Visual observation III, IV, V 
? Shapiro–Wilk’s W-test I, II 
Comparison of data between groups  
? Chi-squared test IV 
? Fisher´s exact probability test I, II, V 
Non-parametric tests  
? Mann–Whitney U-test I, II, V 
? Kruskal–Wallis one-way ANOVA with 
multiple comparison Z-value test 
I, II, IV 
? Repeated measures ANOVA III, IV 
? Analysis of variance (ANOVA) III 
Correlation between different parameters  
? Pearson´s correlation I, II 
? Logistic regression I, II 
? Multiple regression I, II, IV  
 
In Study V, power calculation showed that 18 cases and 19 controls would 
be needed for a power of 80% at a p level of 0.05 to detect a 5-unit difference 
in mean Matsuda whole-body insulin sensitivity index, with the null 
hypothesis that both group means are equal to the mean of controls (= 9.5) 
(Table 10). 
Normality of distribution among continuous variables was analysed either 
by visual observation (III, IV, V) or Shapiro–Wilk´s W-test (I, II) (Table 10). 
For continuous variables, the non-parametric Mann–Whitney U-test and 
Kruskal–Wallis one-way ANOVA with multiple comparison Z-value tests 
were used to compare groups (I, II, IV). For categorial data, the chi-squared 
test (IV) and Fisher’s Exact test (I, II, V) were used to compare groups. 
Correlation between FABP4 levels (I), Angptl6 levels (II) and clinical 
parameters were performed by using Pearson´s correlation method. Logistic 
regression analysis was performed to explore the variables associated with 
indices of pre-eclampsia, using PIH as the dependent variable. Multiple 
regression analysis was performed in Study I using change of blood glucose 
(from 04.00 to 08.00 h) as the dependent variable and chronic hypertension 
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and obesity (BMI ≥ 28 kg/m2) as independent variables. In Studies I and II 
multiple regression analysis was performed by using PIH as the dependent 
variable.  
Probability values of < 0.05 were considered statistically significant in all 
analyses. 
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6 RESULTS 
Detailed results are given in the original publications and therefore only the 
main results are presented here. 
6.1 CHARACTERISTICS OF THE STUDY WOMEN 
Women with subsequent PIH (I, II) 
There were no significant differences in clinical characteristics of the study 
groups (Table 11). Detailed data is in original papers summarized according 
to pregnancy outcome.  
All women were normotensive in the first trimester, but women who 
developed PIH had significantly higher SBPs and DBPs from the first to the 
third trimesters of pregnancy compared with women who stayed 
normotensive (data not shown).  
Table 11. Characteristics of the study women according to pregnancy outcome in 
Studies I and II. 
 PIH Normotensive p 
Study I    
n 26 46  
Age at 24 weeks of gestation 
(years) 
30.9 ± 6.3 31.1 ± 4.6 0.8 
Pre-pregnancy BMI (kg/m2) 28.6 (24.7–36.5) 27.1 (24.2–36.3) 0.2 
BMI at time of delivery (kg/m2) 33.9 ± 3.4 33.2 ± 3.6 0.3 
Weight gain during pregnancy (kg) 12.9 ± 8.2 14.4 ± 6.9 0.5 
Values are shown as mean ± SD, median (range). 
PIH, pregnancy-induced hypertension; BMI, body mass index. 
 
All 12 women with proteinuric PIH had late-onset pre-eclampsia 
(gestational weeks ≥ 34, data not shown). Of the three women with severe 
pre-eclampsia, all fulfilled the criteria for severe hypertension. Three women 
with pre-eclampsia and one woman with non-proteinuric PIH received 
antihypertensive medication (data not shown). Weeks of gestation at delivery 
and birth weight did not significantly differ between the groups (data not 
shown).  
 
Women during pre-eclampsia (III) 
The women in the three groups were comparable in clinical characteristics 
(Table 12). The two pregnant groups were comparable as regards weeks of 
gestation at time of testing and delivery (data not shown). 
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Table 12. Characteristics of the study groups in Study II 
 Pregnant   
 Pre-eclamptic Normotensive Non-pregnant p a) 
n 11 17 8  
Age (years) 26.7 ± 3.3 28.5 ± 4.2 24.1 ± 4.8 NS 
BMI (kg/m2) 23.3 ± 4.2 26.3 ± 3.6 24.5 ± 4.8 NS 
Gestational weeks at 
testing 
36.8 ± 0.9 37.5 ± 0.9  NS 
Values are shown as mean ± SD.  
BMI, body mass index. 
a) Analysis of variance (ANOVA) 
 
Women with GDM (IV) 
In 1995 GDM was diagnosed in 178 women, with eight twin pregnancies (4% 
of all the mothers). Hypertension complicated 43% of the cases. 
Hypertensive women were comparable with normotensive women in regard 
to maternal age and parity (Table 13). Mothers with chronic hypertension 
with or without superimposed pre-eclampsia were heavier (mean BMI ± SD, 
31.6 ± 7.4 kg/m2) than their normotensive controls (25.7 ± 6.0 kg/m2, p < 
0.0001) (Table 13). Seventeen women received anti-hypertensive medication 
during their pregnancies. There were no differences in maternal use of anti-
hypertensive therapy between hypertension groups. None of the women 
received corticosteroid treatment prior to the blood glucose measurements.  
Table 13. Characteristics of the study groups in Study IV 
 Normotensive Proteinuric and 
non-proteinuric 
PIH 
CHT and 
superimposed PE 
p 
n (%) 102 (57.3%) 34 (19.1%) 42 (23.6%)  
Age (years) 32.7 ± 5.3 33.8 ± 6.0 32.8 ± 5.3 NS 
BMI (kg/m2) 25.7 ± 6.0 28.9 ± 7.0 31.6 ± 7.4  < 0.0001 a) 
Nulliparity n (%) 24 (23.5%) 13 (38.2%) 14 (33.3%) NS 
Values are shown as mean ± SD. PIH, pregnancy-induced hypertension; CHT, chronic 
hypertension; PE, pre-eclampsia; BMI, body mass index. a) Kruskal–Wallis one-way ANOVA 
with multiple comparison Z-value test in mothers with chronic hypertension with or without 
superimposed PE compared with normotensive mothers 
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Women in the perimenopausal period (V) 
The baseline characteristics of the study groups were comparable (Table 14). 
Five of the women had had early-onset pre-eclampsia (weeks of gestation < 
34) and 13 had had late-onset pre-eclampsia (weeks of gestation ≥ 34). 
Sixteen women had severe pre-eclampsia. All women with early-onset pre-
eclampsia had a severe disease. 
Table 14. Characteristics of the study groups in Study V 
 Pre-eclampsia Controls p a) 
n 18 19  
Age at the time of the study  48.9 (44–54) 49.3 (42–55) NS 
Age at the time of index pregnancy 24.2 (20–31) 25.8 (17–31) NS 
Years since delivery 23.4 (21–27) 23.7 (23–26) NS 
BMI at the time of the study (kg/m2) 26.4 ± 4.5 (21–39) 25.1 ± 5.2 (18–39) NS 
Values are shown as median (range) or mean ± SD (range). 
BMI, body mass index. 
a) Mann–Whitney U-test. 
6.2 INSULIN RESISTANCE 
Women with subsequent PIH (I, II) 
Whole-body ISI and HOMA-IR at 24 weeks and fasting, 1-hour and 2-hour 
insulin levels were the same in the two groups, irrespective of subsequent 
hypertension (data not shown). At 24 weeks the whole-body ISI did not 
correlate with markers of sympathetic over-activity; noradrenaline at supine 
resting, noradrenaline after 10 min standing, SBP after 10 min standing or 
with ΔSBP (data not shown). At 24 weeks of gestation no correlation was 
observed between insulin sensitivity biomarkers FABP4 or Anptl6 and 
whole-body ISI. 
At 32 weeks of gestation fasting blood glucose levels were the same in the 
two groups, irrespective of subsequent hypertension (data not shown). 
 
Women with GDM (IV) 
Areas under the glucose curve (glucose AUCs) in the hypertensive groups 
were equal to those in their normotensive controls (Table 15). Diurnal blood 
glucose levels at all time points (from 08.00 to 08.00 h) were similar in 
hypertensive groups and in normotensive controls (data not shown). In 
women with chronic hypertension we observed a significant rise in blood 
glucose values in the early morning hours (from 04.00 to 08.00 h), whereas 
they decreased in the normotensive women (Table 15).  
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Table 15. Blood glucose values in women with GDM with and without hypertension in 
Study IV 
 Normotensive Proteinuric and non-
proteinuric PIH 
CHT and 
superimposed PE 
p 
Blood glucose at 
08.00 (mmol/l) 
4.7 (4.3_5.2) 4.7 (4.4–5.5) 4.9 (4.6–5.3) 0.08 
Blood glucose at 
04.00 (mmol/l) 
4.7 (4.3–5.1) 4.6 (4.2–5.0) 4.7 (4.3–5.0) 0.6 
Blood glucose at 
08.00 (mmol/l)  
4.5 (4.3–4.9) 4.5 (4.2–4.9) 4.8 (4.6–5.1) 0.051 
Area under glucose 
curve (mmolh/l) 
103 (95–109) 101 (97–112) 100 ( 96–108) 0.9 
Average change 
(from 04.00 to 
08.00 h) (mmol/l) 
-0.1 (-0.3 to 0.2) -0.1 (-0.2 to 0.4) 0.2 (-0.1 to 0.4)  0.03 
a) 
Values are shown as median (interquartile range (IQR)).  
PIH, pregnancy-induced hypertension; PE, pre-eclampsia; CHT, chronic hypertension. 
a) Kruskal–Wallis one-way ANOVA with multiple comparison Z-value test in mothers with 
chronic hypertension with and without superimposed PE compared with normotensive 
mothers. 
 
In the obese women (BMI ≥ 28 kg/m2, n = 109) the early morning blood 
glucose rise was higher [median, IQR, 0.1 (-0.2 to 0.5) mmol/l] compared 
with the non-obese women (BMI < 28 kg/m2, n = 69), [0 (-0.3 to 0.2) 
mmol/l, p = 0.01]. In regression analysis, both BMI and chronic 
hypertension were significantly associated with a blood glucose rise from 
04.00 to 08.00 h. However, when both factors were included in the multiple 
regression model, neither showed a significant independent effect. 
 
Women in the perimenopausal period (V) 
Insulin sensitivity (Matsuda whole-body ISI, glucose AUC and insulin AUC) 
was similar in women with a history of pre-eclamptic pregnancy and those 
with a history of normotensive pregnancy. Insulin AUC was higher in obese 
(BMI ≥ 30 kg/m2) and overweight (BMI 25–30 kg/m2) women with prior 
pre-eclampsia than in normal weight (BMI < 25 kg/m2) women with prior 
pre-eclampsia (p = 0.008). Among the controls such a difference was not 
seen (data not shown).  Only in women with a history of pre-eclamptic 
pregnancy did waist circumference correlated negatively with insulin 
sensitivity (p = 0.03).  
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Metabolic syndrome 
The waist-hip ratio, blood pressure, heart rate and lipid and lipoprotein 
levels in the groups were comparable (data not shown). In the pre-eclampsia 
group, previously diagnosed hypertension was more common than in 
controls (44 % [8/18] versus 5% [1/19], p = 0.008). 
At the time of the study there was no difference in metabolic syndrome 
between the groups (Table 16). Of women with previous pre-eclampsia, 17% 
(3/18) had metabolic syndrome versus 11% (2/19) of the controls (Table 16). 
Of the study women, 22% (4/18) were obese (BMI ≥ 30 kg/m2) versus 16% 
(3/19) of the controls. All women with metabolic syndrome were obese or at 
least overweight.  
Table 16. Metabolic syndrome among premenopausal women with a pre-eclamptic 
history. Diagnostic criteria were based on the New International Diabetes Federation 
definition (IDF) (Alberti K 2006). 
 Pre-eclampsia Controls p a) 
n 18 19  
Waist circumference ≥ 80 cm 8/18 (44%) 9/19 (47%) NS 
Triglycerides ≥ 1.7 mmol/l 1/18 (6%) 2/19 (11%) NS 
HDL cholesterol < 1.29 mmol/l 3/18 (17%) 2/19 (11%) NS 
Systolic BP ≥ 130 mmHg 11/18 (61%) 6/19 (32%) NS 
Diastolic BP ≥ 85 mmHg 7/18 (39%) 6/19 (32%) NS 
Medical treatment of  
previously diagnosed 
hypertension 
4/18 (22%) 1/19 (5%) NS 
FPG ≥ 5.6 mmo/l 1/18 (6%) 1/19 (5%) NS 
Previously diagnosed DM2 1/18 (6%) 0/19 NS 
Metabolic syndrome 3/18 (17%) 2/19 (11%) NS 
Values are shown as n (%). HDL, high-density lipoprotein; BP, blood pressure; FPG, fasting 
plasma glucose; DM2, diabetes mellitus type 2.  
a) Fisher´s exact test. 
 
6.3 FATTY ACID-BINDING PROTEIN 4 
In Study I, at 24 weeks and at 32 weeks mean fasting FABP4 levels tended to 
be higher in women who subsequently developed PIH than those in the 
normotensive group (Table 17). Since maternal FABP4 concentrations were 
not normally distributed, Table 17 also displays median fasting FABP4 levels 
at 24 weeks and at 32 weeks of gestation without a trend of significantly 
increased FABP4 levels in women with subsequent PIH. In the subgroup of 
proteinuric PIH (pre-eclampsia), FABP4 levels at 24 weeks and at 32 weeks 
were the same as in normotensive women (data not shown). 
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Table 17. Serum fatty acid-binding protein4 (FABP4) levels at 24 and at 32 weeks of 
gestation 
 PIH Normotensives p a) 
n 26 46  
Fasting FABP4 at 24 wk 
(ng/ml) 
29.4 ± 19.2 
20.1 (13.1–72.9) 
21.7 ± 9.2 
19.2 (10.5–49.7) 0.2 
Fasting FABP4 at 32 wk 
(ng/ml) 
45.1 ± 46.5 
25.9 (12.4–213.7) 
26.4 ± 10.9 
23.0 (13.2–59.5) 0.4 
FABP4 difference from 24 
wk to 32 wk (ng/ml) 
13.7 ± 34.8 
1.4 (-21.1–144.1) 
4.6 ± 11.2 
3.7 (-27.0–29.0) 0.8 
Values are shown as mean ± SD and median (range).  
PIH, pregnancy induced hypertension; FABP4, adipocyte fatty acid-binding protein 4. 
a)  The Mann–Whitney U-test was used to compare PIH cases and normotensive controls.  
 
Univariate correlations 
Fasting levels of FABP4 at 24 weeks correlated inversely and significantly 
with weight gain during pregnancy (r = -0.49, p = 0.02), SBP after 10 min 
standing (-0.46, 0.03) and ΔSBP (-0.56, 0.006) in women with PIH. In 
women who remained normotensive, fasting levels of FABP4 at 24 weeks 
correlated positively with pre-pregnancy BMI (r = 0.42, p = 0.004), DBP in 
the 1st trimester (0.39, 0.007) and hs-CRP levels (0.30, 0.04).  
 
Logistic and multiple regression analyses 
In logistic regression we examined clinical factors (FABP4 at 24 and 32 
weeks of gestation, FABP4 difference, hs-CRP at 24 and 32 weeks of 
gestation, hs-CRP difference, testosterone at 24 and 32 weeks of gestation, 
age at 24 weeks of gestation, pre-pregnancy BMI, weight gain during 
pregnancy, fP-glucose and ISI at 24 weeks of gestation, SBP after 10 min 
standing, ΔSBP), and pre-eclampsia and PIH were used as the dependent 
variables. In this analysis, apart from SBP after 10 min standing (p = 0.015, 
r2 = 0.085), baseline FABP4 (p = 0.04, r2 = 0.060) was the only variable 
associated with the development of PIH. In multiple regression analysis, 
both SBP after 10 min standing (p = 0.002, r2 = 0.22) and FABP4 at 24 
weeks of gestation (p = 0.003, r2 = 0.22) correlated positively with the 
development of PIH. 
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6.4 SYMPATHETIC OVER-ACTIVITY 
Women with subsequent PIH (I, II) 
In Study I, plasma noradrenaline levels after supine resting at 24 weeks were 
the same in the study groups (Table 18), but after 10 min standing plasma 
noradrenaline levels tended to be higher as early as at 24 weeks of gestation 
in women with subsequent PIH (Table 18, A.T. et al. unpublished data). At 
32 weeks, women with subsequent hypertension had higher noradrenaline 
levels than normotensive women and the noradrenaline difference from 24 
weeks to 32 weeks was significantly higher, accordingly (Table 18). 
Plasma adrenaline levels differed neither at 24 weeks nor at 32 weeks of 
gestation between the groups (Table 18, A.T. et al. unpublished data). In 
Study II, in the subgroup of Angptl6 measurements at 32 weeks of gestation, 
fasting plasma adrenaline levels were significantly higher in women with 
non-proteinuric PIH (median 105, range 57–222 pmol/l, p = 0.02) compared 
with normotensive controls (median 73, range 25–136) (data not shown). 
Plasma ghrelin levels were the same in the study groups at 24 and 32 
weeks of gestation. Even in the modified orthostatic test the upright position 
did not affect ghrelin levels (Table 18, A.T. et al. unpublished data). 
 
At 32 weeks, fasting levels of FABP4 did not correlate with serum 
noradrenaline levels (data not shown). 
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Table 18. Serum noradrenaline, adrenaline and ghrelin levels at 24 and at 32 weeks of 
gestation  
 PIH Normotensive 
 
P a) 
n 26 46  
Noradrenaline (pmol/l) at 
24 weeks of gestation after 
supine resting 
1340 (554–2300) 1190 (355–3790) 0.1 
Noradrenaline (pmol/l) at 
24 weeks of gestation after 
10 min standing 
2905 (1330–6470) 2450 (979–4420) 0.07 
Noradrenaline difference 
from supine to upright 
position (pmol/l) 
1485 (361–4680) 1220 (214–2899) 0.2 
Noradrenaline (pmol/l) at 
32 weeks of gestation 
1985 (1070–3680) 1540 (712–3770) 0.04 
Noradrenaline difference 
from 24 to 32 weeks of 
gestation (pmol/l) 
748.7 ± 523.3 
600 (100–1890) 
453.6 ± 801.2 
380 (-1230–2320) 
0.05 
Adrenaline (pmol/l) at 24 
weeks of gestation after 
supine resting 
33 (14–147) 47 (19–120) 0.2 
Adrenaline (pmol/l) at 24 
weeks of gestation after 10 
min standing 
49 (19–243) 54 (17–130) 0.9 
Adrenaline difference from 
supine to upright position 
(pmol/l) 
10 (-18–156) 10 (-38–47) 0.8 
Adrenaline (pmol/l) at 32 
weeks of gestation 
90 (36–222) 80 (25–166) 0.9 
Adrenaline difference from 
24 to 32 weeks of gestation  
(pmol/l) 
46 (-34–168) 41 (-89–100) 0.5 
Ghrelin (pmol/l) at 24 
weeks of gestation after 
supine resting 
127 (29–655) 122 (26–597) 0.4 
Ghrelin (pmol/l) at 24 
weeks of gestation after 10 
min standing 
149 (77–1610) 135 (59–642) 0.8 
Ghrelin difference from 
supine to upright position 
(pmol/l) 
17 (-520–966) 12 (-65–510) 0.8 
Ghrelin (pmol/l) at 32 
weeks of gestation 
132 (39–1160) 107 (57–316) 0.2 
Values are shown as mean ± SD and median (range). PIH, pregnancy-induced 
hypertension.  
a) The Mann–Whitney U-test was used, comparing PIH vs. normotensive controls. 
 
In Study I, in the orthostatic test SBP and DBP in supine resting and after 
10 minutes standing were significantly higher in women who developed PIH 
(Table 19, A.T. et al. unpublished data). Mean arterial pressures (MAPs) in 
supine resting and after 10 minutes standing were significantly higher in 
women who developed PIH (Table 19, A.T. et al. unpublished data). Heart 
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rate in supine resting, after 10 minutes standing and heart rate difference did 
not differ between women with subsequent hypertension compared with 
normotensive women (A.T. et al. unpublished data). 
At 24 weeks of gestation, in the modified orthostatic test, plasma 
noradrenaline levels correlated with systolic blood pressure after 10 min 
standing and with mean arterial pressure after 10 min standing in all 
patients, but only with systolic blood pressure after 10 min standing in 
women with subsequent proteinuric PIH (A.T. et al. unpublished data). 
Table 19. The orthostatic test at 24 weeks 
 PIH Normotensive p a) 
n 26 46  
SBP supine resting (mmHg) 116 (88–150) 99 ( 80–122) < 0.001 
DBP supine resting (mmHg) 69 ± 9 62 ± 11 0.007 
SBP after 10 min standing (mmHg) 117 ± 12 108 ± 13 0.009 
DBP after 10 min standing (mmHg) 79 ± 9 72 ± 8 0.005 
MAP supine resting (mmHg) 83 ± 10 75 ± 10 0.002 
MAP after 10 min standing (mmHg) 91 ± 8 84 ± 9 0.004 
Values are shown as means ± SD or median (range).  
PIH, pregnancy-induced hypertension; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; HR, heart rate; MAP, mean arterial pressure. 
MAP = ([2 × DBP] + SBP)/3. 
a)  The Mann–Whitney U-test was used to compare PIH cases with normotensive controls. 
 
In the subgroup of Angptl6 measurement, the difference in supine resting 
DBP between women who developed PIH and women who remained 
normotensive did not reach statistical significance (II). 
 
Women during pre-eclampsia (III) 
At baseline, after 30 min in the left-lateral position noradrenaline levels were 
lowest in normotensive pregnant women (Table 20). At all time points, 
normotensive pregnant women had significantly lower noradrenaline levels 
than non-pregnant women (p < 0.05) (Table 20). In pre-eclamptic women 
noradrenaline levels were higher than in normotensive pregnant women at 
all time points (p < 0.01) (Table 20).  
The change from left-lateral to upright position and from upright back to 
left-lateral position resulted in greater changes in noradrenaline levels in 
pre-eclamptic women than in normotensive pregnant women (Table 20). 
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Table 20. Catecholamine levels in Study III 
 Pregnant   Change in 
body 
position 
 Pre-
eclamptic 
Normotensive Non-
pregnant 
p  p 
 
n 11 17 8   
Baseline LL 
noradrenaline 
(pmol/l) 
 
1267 ± 429 702 ± 365  1247 ± 554 <0.01 a) 
<0.05 b) 
NS 
Supine 
noradrenaline 
(pmol/l) 
1321 ± 498 850 ± 570 1430 ± 437 <0.01 a) 
<0.05 b) 
NS 
LL noradrenaline 
(pmol/l) 
1175 ± 416 698 ± 483 1255 ± 245 <0.01 a) 
<0.05 b) 
NS 
Upright 
noradrenaline 
(pmol/l) 
2564 ± 
1162 
1566 ± 901 2634 ± 889 <0.01 a) 
<0.05 b) 
<0.05 d) 
LL noradrenaline 
(pmol/l) 
1206 ± 468 718 ± 425 1269 ± 345 <0.01 a) 
<0.05 b) 
<0.05 d) 
Baseline LL 
adrenaline (pmol/l) 
131 ± 62 54 ± 37 57 ± 23 <0.05 c) NS 
Supine adrenaline 
(pmol/l) 
135 ± 74 62 ± 43 48 ± 30 NS NS 
LL adrenaline 
(pmol/l) 
114 ± 87 138 ± 267 65 ± 49 NS NS 
Upright adrenaline 
(pmol/l) 
237 ± 206 125 ± 83 225 ± 380 NS NS 
LL adrenaline 
(pmol/l) 
112 ± 79 71 ± 56 63 ± 22 NS NS 
Values are shown as mean ± SD. LL, left-lateral position. 
a) Fisher´s least significance difference test comparing pre-eclamptic with normotensive 
pregnant women 
b) Fisher´s least significance difference test comparing normotensive pregnant women with 
non-pregnant women. 
c) Fisher´s least significance difference test comparing pre-eclamptic with normotensive 
groups 
d) ANOVA for repeated measures comparing pre-eclamptic with normotensive pregnant 
women. First a change from left-lateral to an upright position and then from upright back to a 
left-lateral position. 
 
At baseline, after 30 min in the left-lateral position adrenaline levels were 
higher in pre-eclamptic patients than in the other two groups (Table 20). 
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Changes in adrenaline levels with body position were not different between 
the groups. 
Plasma renin activity was higher in pre-eclamptic than in normotensive 
pregnant women at all time points (p < 0.05) (Table 21). Pre-eclamptic 
women had higher levels of plasma renin activity than non-pregnant women 
(p < 0.001) and changes in plasma renin activity were greater in pre-
eclamptic than in normotensive pregnant women moving from the left-
lateral to an upright position (p < 0.05) (Table 21). 
Table 21. Plasma renin activity observed in Study III 
 Pregnant   Change 
in body 
position 
 Pre-
eclamptic 
Normotensive Non-
pregnant 
p  p 
 
n 11 17 8   
Baseline LL plasma 
renin activity 
(nmol/l/h) 
2.6 ± 1.3 1.8 ± 0.7 0.9 ± 0.2 <0.05 a) 
<0.001 b) 
<0.05 c) 
NS 
Supine plasma renin 
activity (nmol/l/h) 
2.7 ± 1.4 2.0 ± 0.9 0.9 ± 0.3 <0.05 a) 
<0.001 b) 
<0.05 c) 
NS 
LL plasma renin 
activity (nmol/l/h) 
2.9 ± 1.3 1.9 ± 0.9 0.9 ± 0.3 <0.05 a) 
<0.001 b) 
<0.05 c) 
NS 
Upright plasma renin 
activity (nmol/l/h) 
3.9 ± 2.2 2.3 ± 0.8 1.1 ± 0.3 <0.05 a) 
<0.001 b) 
<0.05 c) 
<0.05 
d) 
LL plasma renin 
activity (nmol/l/h) 
3.3 ± 1.6 1.9 ± 0.8 1.0 ± 0.3 <0.05 a) 
<0.001 b) 
<0.05 c) 
NS 
Values are shown as mean ± SD.  
LL, left-lateral position. 
a) Fisher´s least significance difference test comparing pre-eclamptic with normotensive 
pregnant women 
b) Fisher´s least significance difference test comparing pre-eclamptic with non-pregnant 
women 
c) Fisher´s least significance difference test comparing normotensive pregnant women with 
non-pregnant women. 
d) ANOVA for repeated measures comparing pre-eclamptic with normotensive pregnant 
women. Change from left-lateral to upright position. 
 
Plasma natriuretric peptide and endothelin-1 levels were similar in pre-
eclamptic and normotensive pregnant women and changes with posture were 
not different between the three groups (data not shown).  
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A change from a left-lateral position to a supine position decreased SBP in 
pre-eclamptic women and increased it in the normotensive groups (data not 
shown). The difference between pre-eclamptic and normotensive pregnant 
women was statistically significant (p < 0.001). When the women returned to 
a left-lateral position an opposite change appeared in SBP; in pre-eclamptic 
women SBP increased and it decreased in the normotensive groups, the 
difference between the two pregnant groups being significant (p < 0.01; data 
not shown). 
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6.5 ANDROGENS 
Women with subsequent PIH (I, II) 
In Study I maternal serum testosterone, SHBG and calculated free 
testosterone (cfT) levels at 24 and at 32 weeks of gestation were the same 
regardless of hypertension during pregnancy (Table 22). 
Table 22. Serum testosterone levels at 24 and at 32 weeks of gestation 
 PIH Normotensive p a) 
n 26 46  
S-Testosterone (nmol/l) at 24 wk 2.6 (1.2 – 5.9) 3.0 (1.1 – 19.6) 0.4 
S-Testosterone (nmol/l) at 32 wk  2.7 (1.6 – 6.8) 2.9 (1.0 – 16.8) 0.8 
cfT (pmol/l) at 24 wk  1.4 (0.7 – 3.3) 1.6 (0.6 – 10.8) 0.4 
cfT (pmol/l) at 32 wk  1.5 (0.9 – 3.8) 1.6 (0.6 – 9.2) 0.8 
S-SHBG (nmol/l) at 24 wk  370 (240 – 660) 411 (230 – 630) 0.3 
S-SHBG (nmol/l) at 32 wk  432 (320 – 720) 486 (334 – 890) 0.3 
Values are shown as means ± SD and median (range).  
PIH, pregnancy-induced hypertension; cfT, calculated free testosterone; SHBG, sex 
hormone-binding globulin. 
a) The Mann–Whitney U-test was used in comparisons. 
 
Univariate correlation 
We found no significant correlation between maternal testosterone at 24 or 
at 32 weeks versus pre-pregnancy BMI, BMI at time of delivery, weight gain 
during pregnancy, fasting blood glucose and whole-body ISI at 24 weeks in 
women who developed PIH or in those who remained normotensive (data 
not shown). At 24 and at 32 weeks of gestation there was no correlation 
between maternal FABP4 levels and testosterone levels (data not shown). 
 
Women in the perimenopausal period (V) 
The free androgen index (FAI) and total and calculated free testosterone 
levels were similar in the two groups (Table 23). Of the women with previous 
pre-eclampsia, 11% (2/18) had PCOS, versus none of the controls. 
Only 11% (2/18) of the women with prior pre-eclampsia and 35% (6/17) of 
the control women had some climacteric symptoms. To evaluate menopausal 
transition we calculated median FSH levels in the patient and control groups. 
The women were then categorized as being above or below the median FSH 
level in each group. In women with prior pre-eclampsia and FSH below the 
median, calculated free testosterone levels were higher than in women with 
prior pre-eclampsia and FSH above the median (median 13.4 pmol/l, range 
8.0–22.5 vs. 7.1 pmol/l, 5.1–20.5, p = 0.03). In women with prior 
normotensive pregnancies and FSH levels below the median and FSH above 
the median calculated free testosterone levels were the same (data not 
shown). In women with prior pre-eclampsia and normotensive pregnancies 
and FSH below medians calculated free testosterone and total testosterone 
levels were similar (data not shown).  
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Table 23. Androgenic characteristics and PCOS in premenopausal women with a pre-
eclamptic history 
 Pre-eclampsia Controls  p a) 
n 18 17 c) NS 
S-Testosterone (nmol/l) 0.8 (0.4 – 2.3) 0.7 (0.3 – 1.7) NS 
cfT (pmol/l) 9.8 (5.1 – 22) 8.4 (3.5 – 21) NS 
S-SHBG (nmol/l) 50.5 (26 – 125) 61.0 (13 – 174) NS 
DHEAS (μmol/l) 2.6 (0.9 – 6.5) 2.5 (0.7 – 4.7) NS 
FAI 1.7 (0.6 – 4.6) 1.3 (0.4 – 3.0) NS 
FSH (IU/l) 5.9 (2.9 – 93) 6.0 (2.1 – 63) NS 
FSH <10 IU/l, n (%) 14/18 (78%) 11/17 (65%) NS b) 
S-Testosterone (nmol/l) if FSH <10 IU/l 0.8  (0.4 – 2.3) 0.8 (0.3 – 1.7) NS 
S-Testosterone (nmol/l) if FSH >10 IU/l 0.6 (0.4 – 1.2) 0.6 (0.4 – 0.9) NS 
cfT (pmol/l) if FSH <10 IU/l 10.5 (6.6 – 22) 9.0 (3.5 – 21) NS 
cfT (pmol/l) if FSH >10 IU/l 6.1 (5.1 – 20) 6.2 (4.8 – 11.4) NS 
PCOS, n (%) 2/18 (11%) 0/17 NS b) 
Values are shown as median (range).  
cfT, calculated free testosterone; SHBG, sex hormone-binding globulin; DHEAS, 
dehydroepiandrosterone sulphate; FAI, free androgen index; FSH, follicle-stimulating 
hormone. 
a) The Mann–Whitney U-test and b) Fisher´s exact test. 
c) Two women were excluded from hormone analyses because one used estradiol valerate-
cyproterone acetate tablets and one used cyclic norethisterone. 
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6.6 INFLAMMATION 
Women with subsequent PIH (I, II) 
In Study I, in women at 24 and 32 weeks of gestation there were no 
differences in hS-CRP levels between the study groups (women with 
subsequent PIH vs. normotensive controls) (Table 24).  
Table 24. Serum high-sensitivity C-reactive protein (hs-CRP) levels at 24 and at 32 
weeks of gestation  
 PIH Normotensive p b) 
n 26 46  
hs-CRP at 24 wk (mg/l)a) 4.8 (0.7–9.8) 3.9 (0.7–9.8) 0.2 
hs-CRP at 32 wk (mg/l)a)  4.8 ± 2.4 3.6 ± 2.2 0.06 
Values are shown as means ± SD and median (range).  
PIH, pregnancy-induced hypertension; hs-CRP, high-sensitivity C-reactive protein. 
a) From hs-CRP calculations we excluded women with hs-CRP levels of > 10 mg/l, because 
of the risk of acute infection (at 24 weeks of gestation five women with PIH and eight 
normotensive women and at 32 weeks of gestation four with PIH and seven normotensive 
women).  
b) The Mann–Whitney U-test was used in comparisons. 
 
Univariate correlations 
There were no correlations between maternal FABP4 levels and hS-CRP 
levels at 24 weeks or at 32 weeks. Serum hs-CRP levels at 24 weeks, but not 
at 32 weeks, correlated positively with pre-pregnancy BMI (r = 0.39, p = 
0.05), but inversely with weight gain during pregnancy (r = -0.44, p = 0.03) 
in women with subsequent PIH. On the other hand, in women with 
normotensive pregnancies, at 32 weeks (but not at 24 weeks) serum hs-CRP 
levels correlated positively with pre-pregnancy BMI (r = 0.35, p = 0.04) and 
BMI at time of delivery (r = 0.41, p = 0.01). 
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6.7 ANGIOPOIETIN-LIKE PROTEIN 6 
In Study II, at 24 weeks fasting Angptl6 levels were significantly higher in 
women who subsequently developed PIH with or without proteinuria 
compared with normotensive controls (Table 25, Figure 4). At 32 weeks 
fasting Angptl6 levels tended to be higher in women who developed PIH than 
in those in the normotensive group, but the difference was not statistically 
significant (Table 25, Figure 4). The change in fasting Angptl6 levels between 
24 and 32 weeks of gestation tended to be greater in women who developed 
PIH than in the normotensive group, but the difference was not statistically 
significant (Table 25).  
 
Table 25. Serum angiopoietin-like protein 6 (Angptl6) levels at 24 and at 32 weeks of 
gestation 
 PIH 
 
Normotensive p-value a) 
n 24 23  
Fasting Angptl6 at 24 wk (ng/ml) 252 (85 – 536) 145 (28 – 455) 0.02 
2-h Angptl6 at 24 wk (ng/ml) 232 (28 – 816) 221 (44 – 549) NS 
Fasting Angptl6 at 32 wk (ng/ml) 318 (89 – 945) 224 (65 – 636) NS 
Angptl6 difference from 24 to 32 
wk of gestation  (ng/ml) 
108 (-159 to 574) 39 (-224 to 497) NS 
Values are shown as median (range). 
PIH, pregnancy-induced hypertension; Angptl6, angiopoietin-like protein 6. 
a) The Mann–Whitney U-test was used in comparisons. 
 
In the subgroup of subsequent non-proteinuric PIH, at 24 weeks of 
gestation fasting Angptl6 levels were significantly higher than in the 
normotensive controls (median 293 ng/ml, range 121–531, vs. 145 ng/ml, 
range 28–455, p = 0.03), but a similar difference in the subgroup of 
subsequent proteinuric PIH (173 ng/ml, range 85–536) did not reach 
statistical significance (Figure 4). At 32 weeks of gestation the differences in 
Angptl6 levels in the subgroups of non-proteinuric PIH (median 348 ng/ml, 
range 104–945) and proteinuric PIH (222 ng/ml, 89–633) compared with 
normotensive controls (224 ng/ml, 65–636) did not reach statistical 
significance (Figure 4).  
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Figure 4 Box plots of serum Angptl6 levels at 24 weeks of gestation and at 32 weeks in 
women with non-proteinuric PIH, proteinuric PIH (pre-eclampsia), all cases of PIH and in 
normotensive women. Medians, interquatile ranges and ranges are displayed. * p=0.03 for 
women with non-proteinuric PIH compared with normotensive controls, † p=0.02 for women 
with PIH compared with normotensive controls. 
We calculated a receiver operating characteristic (ROC) curve for PIH and 
proteinuric PIH (pre-eclampsia) to see if assay of Angptl6 could be used as a 
diagnostic test. It turned out that Angptl6 measurements failed to predict 
future PIH/pre-eclampsia. For PIH the area under the curve was 0.35 and for 
pre-eclampsia, 0.46. 
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Univariate correlations 
In all women, fasting levels of Angptl6 at 24 weeks did not correlate with pre-
pregnancy BMI or BMI at the time of delivery. In women with PIH the 
correlation between fasting levels of Angptl6 at 24 weeks and pre-pregnancy 
BMI was inverse and significant (r = -0.48, p = 0.02), but there was no 
correlation with BMI at the time of delivery. Weight gain during pregnancy 
(all women) did not correlate with fasting Angptl6 levels at 24 weeks of 
gestation, but in women with subsequent PIH the correlation was positive 
and significant (r = 0.45, p = 0.04). At 32 weeks, Angptl6 and weight gain 
during pregnancy still correlated positively in women with PIH (r = 0.52, p = 
0.03), but not in all women together. 
At 24 weeks of gestation serum fasting Angptl6 levels correlated with 
diastolic blood pressure after 10 min standing and with mean arterial 
pressure after 10 min standing (modified orthostatic test), but serum fasting 
Angptl6 levels did not correlate with subsequent blood pressure parameters. 
 
Logistic and multiple regression analyses 
Using logistic regression analysis we examined the association with clinical 
factors, with pre-eclampsia and PIH being used as the dependent variables. 
In this analysis PIH was associated with SBP after 10 min standing (p = 0.01, 
r2 = 0.13) and with fasting Angptl6 levels at 24 weeks of gestation (p = 0.02, 
r2 = 0.11). In multiple regression analysis only SBP after 10 min standing 
correlated positively (p = 0.02, r2 = 0.21) with the development of PIH. 
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7 DISCUSSION 
7.1 INSULIN RESISTANCE 
Before pregnancy-induced hypertension 
Our study showed no signs of increased insulin resistance at 24 weeks of 
gestation in nulliparous women who were subsequently hypertensive 
compared with women who remained normotensive. This is in contrast to 
previous studies where women with subsequent pre-eclampsia were already 
more insulin resistant in the first trimester (D'Anna R 2006) and in mid-
trimester (Hauth J 2011). The lack of expected insulin resistance in our study 
could be explained by different timing of hypertension and differences in 
ethnicity (Hauth J 2011), parity (D´Anna R 2006, Hauth J 2011) and age. 
One of the previous studies was a case-control study with older and 
multiparous women (D´Anna R 2006). The other consisted of a secondary 
analysis of a randomized trial after antioxidant treatment and with younger 
women than in our study (Hauth J 2011). In our study women had late-onset 
hypertension without increased insulin resistance, at least in the second 
trimester of pregnancy. 
 
During pregnancy-induced hypertension 
In our fourth study women with GDM showed a greater rise in blood glucose 
in the early morning hours among those with chronic hypertension, whereas 
blood glucose levels decreased in the normotensive women. This is in 
agreement with the results of an earlier study where it was suggested that 
pregnant women with both chronic hypertension and GDM may be more 
insulin-resistant than those with GDM alone (Caruso A 1999). The early 
morning glucose rise in women with chronic hypertension may have resulted 
from the dawn phenomenon seen in subjects with type 2 diabetes (Porcellati 
F 2013). In type 2 diabetes fasting hyperglycaemia has been attributed to a 
transient increase in hepatic glucose production at dawn in the absence of 
compensatory insulin secretion (Porcellati F 2013). The role of the dawn 
phenomenon in pregnant women with glucose intolerance is still unknown 
(Mandujano A 2013). 
We did not study insulin sensitivity during overt pre-eclampsia, but the 
insulin resistance seen during normal pregnancy (Barbour L 2007) has been 
found to be further enhanced in cases of non-proteinuric (Seely E 2003) and 
proteinuric PIH (pre-eclampsia) (Kaaja R 1999a, Seely E 2003). However, 
women with GDM who later develop pre-eclampsia have not been reported 
to be more insulin resistant than those who remain non-pre-eclamptic 
(Montoro M 2005).  
It seems that increased insulin resistance is a relatively late phenomenon 
in GDM women who develop hypertensive pregnancy. Apart from the dawn 
 77 
phenomenon, the early morning rise in women with chronic hypertension 
may have resulted from greater insulin resistance and sympathetic over-
activity in these women. Hypertensive pregnant women have been found to 
have higher noradrenaline levels in the early morning hours (Kaaja R 1999b), 
being a sign of increased sympathetic activity. We must be cautious in our 
interpretations, as we measured neither insulin sensitivity nor sympathetic 
activity (MSNA or plasma noradrenaline) in our study. 
 
After pregnancy-induced hypertension 
In our fifth study, 23–24 years after pre-eclamptic pregnancy, there were no 
signs of increased insulin resistance in the premenopausal period, in contrast 
to earlier assumptions.  
Although insulin sensitivity improves postpartum, insulin resistance has 
been seen three months (Kaaja R 1999a) and 18 months after pre-eclamptic 
pregnancy (Wolf M 2004), but it seems to taper off later on, especially in 
normal-weight women. In one study, five years after pre-eclamptic 
pregnancy there was no difference in insulin sensitivity between normal-
weight women with previous pre-eclampsia and normotensive control 
women (Lampinen K 2008). In another study a history of (proteinuric) pre-
eclampsia has been associated with mild hyperinsulinemia seventeen years 
after first pregnancy (Laivuori H 1996), but twenty years after pre-eclampsia 
women had only a tendency toward higher fasting insulin levels, although 
glycosylated haemoglobin levels were significantly higher than in controls 
(Sattar N 2003). In our study insulin resistance did not differ 23–24 years 
after pre-eclamptic vs. normotensive pregnancy. Our result could be 
explained by the fact that in our study women were mostly non-obese. In an 
earlier study, five years after pregnancy, abdominal circumference and 
insulin sensitivity correlated only in women with a history of pre-eclampsia 
(Lampinen K 2008). This was also observed in our study. Although waist 
circumference was still within normal limits in both groups, and similar, it 
correlated with insulin sensitivity only in women with a history of pre-
eclamptic pregnancy. Thus, this group of women is likely to be prone to 
insulin resistance and metabolic syndrome if they gain weight, especially in 
abdominal region. 
Regardless of their proteinuric status (Männistö T 2013), hypertensive 
pregnant women are at an increased risk of later cardiovascular disease 
(Bellamy L 2007, Valdiviezo C 2012). An important risk factor of CVD is 
metabolic syndrome (Galassi A 2006). However, in our study of mostly non-
obese women with a history of pre-eclamptic pregnancy, metabolic syndrome 
was not more common in the premenopausal period than in women with a 
history of normotensive pregnancy. 
It might be that after pre-eclamptic pregnancy only some women have 
persistent insulin resistance and other risk factors common to pre-eclampsia 
and CVD. Women with a history of recurrent PIH have been found to be at a 
higher risk of developing modifiable CVD risk factors such as elevated BMI, 
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elevated blood pressure, an unfavourable lipid profile and diabetes mellitus 
(Lykke J 2009, Magnussen E 2009). This risk is also increased in those with 
early onset pre-eclampsia (Bellamy L 2007). 
Metabolic risk factors are not likely to entirely explain the elevated risk of 
later CVD in women with a history of PIH. Five years after pre-eclamptic 
pregnancy, women have been found to have altered vasorelaxation 
(Lampinen K 2008) and increased levels of plasma noradrenaline (Lampinen 
K 2013). In our study insulin resistance was not increased, at least in the 
premenopausal period, as a sign of increased risk of later CVD in women 
with prior pre-eclampsia. 
7.2 FATTY ACID-BINDING PROTEIN 4 
Our first study showed that in relatively overweight pregnant women, 
maternal serum FABP4 concentrations measured at 24 weeks of gestation 
were associated with the subsequent development of PIH. However, neither 
at 24 weeks nor at 32 weeks of gestation did serum FABP4 concentrations 
significantly differ in women who subsequently developed PIH compared 
with those who remained normotensive. 
In contrast to the results of an earlier study where maternal FABP4 levels 
were higher even before the clinical onset of pre-eclampsia (Scifres C 2012), 
in our study maternal FABP4 levels were similar in the proteinuric subgroup. 
We did not study FABP4 levels during overt pre-eclampsia.  
To the best of our knowledge, this is the first time that maternal FABP4 
levels have been studied in women without proteinuria and before the onset 
of hypertensive pregnancy. Our result strengthens the idea of FABP4 as a 
modulator in metabolic alterations and PIH. However, our study revealed no 
signs of increased insulin resistance at 24 weeks of gestation in women with 
subsequent PIH. 
During pregnancy maternal insulin sensitivity is reduced (Seely E 2003) 
and lipolysis in adipose tissue increased (Diderholm B 2005). Increased 
maternal FABP4 levels have been found to be associated with insulin-
resistant proteinuric PIH (pre-eclampsia) (Fasshauer M 2008, Shangguan X 
2009, Scifres C 2012) and FABP4 could be a marker of increased lipolysis 
and inflammation. During pregnancy FABP4 could link various metabolic 
factors to obesity, as in non-pregnant individuals (Xu A 2006, Xu A 2007). 
Circulating FABP4 levels are higher in overweight/obese than in lean 
individuals (Xu A 2006). In our study pre-pregnancy BMI correlated 
positively with serum FABP4 levels. In PIH, FABP4, pre-pregnancy 
adiposity, and inflammation are most probably metabolically linked together, 
but the specific role of FABP4 in obesity and PIH is still unclear, and it 
possibly has a mechanism of its own.   
The small number of women and lack of normal-weight controls limit the 
statistical significance of our results and ability to establish diagnostic 
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thresholds for maternal serum Angptl6 and FABP4 levels and subsequent 
development of PIH. Including patients with different types of pregnancy-
induced hypertension (pre-eclampsia and non-proteinuric PIH) in a single 
group could lead to bias. In our study both proteinuric and non-proteinuric 
PIH were late-onset, mostly mild diseases without demonstrable foetal 
involvement and the women delivered at term, so women with and without 
proteinuria were analysed as one group, since the pathogenesis is similar 
(Solomon C 2001, Seely E 2003). In late-onset disease endothelial 
dysfunction is much milder than in early-onset pre-eclampsia (< 34 
gestational weeks) (Gilbert J 2008) and the pathophysiology is different in 
these two conditions (Valensise H 2008). 
7.3 SYMPATHETIC OVER-ACTIVITY 
Our first study gave support to the idea that sympathetic activation may 
precede hypertensive pregnancy. It showed that plasma noradrenaline levels 
were higher at 32 weeks of gestation in women with subsequent PIH, but at 
24 weeks of gestation only a tendency toward higher levels of noradrenaline 
was seen after stimulation of the sympathetic nervous system by 10 min 
standing. An upright position at 24 weeks of gestation did not exaggerate the 
difference in noradrenaline levels either.  At 24 weeks of gestation SBP after 
10 min standing was associated with the development of PIH. These changes 
are likely to be associated with increased sympathetic activity in PIH.  
In our study, at 24 weeks of gestation plasma noradrenaline levels 
correlated with systolic blood pressure after 10 min standing (modified 
orthostatic test), but only in women with subsequent proteinuric PIH. At 24 
weeks of gestation we observed no association between factors related to 
sympathetic activity (such as supine resting noradrenaline levels, 
noradrenaline levels after 10 min standing, SBP after 10 min standing and 
ΔSBP) and whole-body ISI. As mentioned earlier, at 24 weeks of gestation 
whole-body ISI was not different in women with subsequent PIH and those 
who remained normotensive. Thus, sympathetic over-activity seems to 
precede the possible insulin resistance in hypertensive pregnancy, but most 
certainly further larger prospective studies are needed, with more accurate 
and sensitive methods of assessing insulin sensitivity (hyperinsulinaemic-
euglycaemic clamp and IGTTs) and sympathetic activity (MSNA). However, 
the use of such invasive methods during pregnancy is limited. 
Our third study showed that women with overt pre-eclampsia had higher 
plasma noradrenaline levels compared with those in normotensive pregnant 
women and the difference was even more obvious when the women were in 
the upright position. Our result is in accordance with those in earlier studies 
(Schobel H 1996, Manyonda I 1998, Kaaja R 1999b) and it strengthened the 
role of sympathetic over-activity in pre-eclampsia.  
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In overweight and obese pregnant women, a hyperactive sympathetic 
nervous system may directly increase the risk of gestational hypertensive 
disorders (Greenwood J 2003, Fischer T 2004, Wang Z 2013). In obesity 
hyperleptinaemia could be related to raised sympathetic activity (Lambert G 
2010, Simonds S 2012, Machleidt F 2013), which could predispose women to 
pregnancy-related hypertension. In our study, at 24 and 32 weeks of 
gestation levels of the leptin inhibitor ghrelin were the same in women with 
subsequent hypertension and in those with normotensive pregnancy and an 
upright position did not affect ghrelin levels. 
Earlier studies have shown that during proteinuric PIH (pre-eclampsia) 
there are increased levels of venous noradrenaline (Manyonda I 1998) and 
increased diurnal venous plasma levels of noradrenaline (Kaaja R 1999b), 
reflecting some evidence of global sympathetic over-activity in this condition. 
However, a plasma noradrenaline measurement has limited sensitivity as an 
index of sympathetic activity (Grassi G 1999), as it shows only a momentary 
reflection of neurotransmitter levels and is subject to changes in 
noradrenaline clearance, and localisation of sympathetic over-activity is not 
revealed (Grassi G 1995). 
Sympathetic over-activity seems to play an important role in the 
pathophysiology of hypertensive pregnancy, as it precedes and is seen to 
prevail after hypertensive pregnancy (Lampinen K 2013), but further studies 
are required.  
7.4 ANDROGENS 
In our first study maternal serum testosterone levels were the same in the 
second and the third trimester of pregnancy in women with subsequent PIH 
and in normotensive women. These results are in agreement with those of a 
previous study on pre-eclamptic women (Tuutti E 2011). Data on androgens 
in non-proteinuric PIH is scarce. We did not study maternal testosterone 
levels during pre-eclamptic pregnancy. In most studies during overt pre-
eclampsia maternal testosterone levels have been elevated compared with 
those in normotensive pregnant women (Acromite M 1999, Serin I 2001, 
Atamer Y 2004). 
In our study, 23–24 years after pre-eclamptic pregnancy, premenopausal 
women did not show signs of increased androgen levels compared with 
women with a history of normotensive pregnancy. Thus, the increased risk of 
CVD in women with a history of hypertensive pregnancy, at least in pre-
eclamptic women, seems not to be related to hyperandrogenism. In our study 
SHBG levels were not decreased, and calculated free testosterone levels and 
the free androgen index were still within normal limits. Women with a 
history of pre-eclamptic pregnancy had higher calculated free testosterone 
levels if FSH was at a premenopausal level, but in women with a history of 
normotensive first pregnancy the same phenomenon was not seen. Our study 
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did not confirm the hypertestosteronism which has been reported 17 years 
after pre-eclamptic pregnancy (Laivuori H 1998). 
In healthy women androgen levels start to decrease during the 
reproductive years before menopause (Davis S 2002). There is an age-related 
reduction in both ovarian and adrenal androgen production. During 
menopausal transition circulating SHBG levels fall (Burger H 2000) and as a 
result free androgen levels rise, but total testosterone levels do not change 
significantly (Burger H 2002). With age, testosterone levels fall gradually 
(Burger H 2002). In our study in women with FSH levels above 10 IU/l, 
androgen levels were the same in women with a history of pre-eclampsia and 
in women with a history of normotensive pregnancy.  
One reason why elevated serum testosterone levels were not observed in 
the perimenopausal period might be our method of testosterone 
measurement. The present mass spectrometric method (LC-MS/MS method) 
of testosterone measurement (Turpeinen U 2008) is more precise for low 
testosterone levels (below 6 nmol/l) than the immunological method used 
before (Laivuori H 1998). The problems of direct immunoasssays for serum 
testosterone without extraction and pre-purification steps have been 
documented (Rosner W 2007). Using a GC-MS reference method for 
testosterone it has been shown that all commercially available immunoassays 
give unreliable results for low testosterone levels in women (Taieb J 2003), 
probably as a result of several interfering factors, such as SHBG and cross-
reactivity among antisera for testosterone. This has been confirmed by 
comparison of immunoassays with LC-MS/MS methods (Wang C 2004). The 
lack of sensitivity and specificity, together with the bias associated with direct 
testosterone immunoassays makes them all unsuitable for accurate analysis 
of testosterone in women.  
Another reason for our result might be that our women with previous pre-
eclampsia tended more often to have PCOS than the controls, but the 
number of patients was low. It is known that before menopause 
hyperandrogenism partly resolves in women with PCOS (Winters S 2000, 
Legro R 2003). This could explain why hyperandrogenism in general was not 
seen in the present study.  
7.5 INFLAMMATION 
In our fifth study, women with subsequent PIH and those with normotensive 
pregnancies had similar hs-CRP levels at 24 and at 32 weeks of gestation.  
Even normal pregnancy provokes an increased maternal systemic 
inflammatory response, at least in the third trimester, and in pre-eclamptic 
pregnancy the inflammatory response is more extreme (Sibai B 2005). In 
previous studies on overt pre-eclampsia, levels of CRP (Teran E 2001), hs-
CRP (Ertas I 2010), TNF-α and IL-6 have been reported to be elevated 
(LaMarca B 2007). In our study, women with subsequent PIH were not 
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heavier than their controls and they had no signs of insulin resistance or 
higher levels of FABP4, which might explain our result. 
We found no correlation between maternal FABP4 levels and hs-CRP 
levels at 24 or 32 weeks in women with subsequent hypertension or in 
controls. In a previous study on non-pregnant women, plasma FABP4 levels 
correlated positively with those of several proinflammatory markers (hs-
CRP, TNF-α receptors and IL-6) (Xu A 2012). At the same time as FAPB4 is 
secreted from adipocytes, inflammation might increase in adipose tissue. In 
our study FABP4 levels were similar between groups, as with the 
inflammation marker hs-CRP. 
Pre-pregnancy adiposity is a strong independent risk factor of PIH 
(Sukalich S 2006, Roberts J 2011) and inflammation is important in the 
causal pathway through which obesity predisposes pregnant women to pre-
eclampsia (Wolf M 2001). FABP4 has been shown to be critical for regulating 
both metabolic and inflammatory responses (Furuhashi M 2011), but our 
results did not confirm that during pregnancy. 
7.6 ANGIOPOIETIN-LIKE PROTEIN 6 
In our second study it was shown for the first time that maternal Angptl6 
levels were already significantly elevated at 24 weeks of gestation, before the 
onset of PIH. These levels increased in all groups over the next 8 weeks, but 
by 32 weeks differences between groups were no longer statistically 
significant. At 24 weeks fasting Angptl6 levels were especially higher in the 
non-proteinuric subgroup, compared with normotensive controls.  
Previous studies have shown that circulating Angptl6 levels are elevated 
in pre-eclampsia compared with those in normotensive pregnant women 
(Stepan H 2009), but in a recent study there were no differences in pre-
eclamptic and normotensive pregnant women (Xia G 2013). However, 
maternal Angptl6 levels have been found to be elevated in pregnant women 
compared with non-pregnant women (Xia G 2013). 
The explanation for elevated serum Angptl6 levels in pre-eclampsia and 
the elevation preceding onset of PIH is not known. Even though there were 
no signs of increased insulin resistance at 24 weeks of gestation in our study, 
increased Angptl6 values in PIH and pre-eclampsia might be a response to 
insulin resistance, perhaps tending to inhibit its further progression to overt 
diabetes mellitus. Secondly, elevated Angptl6 levels before onset of pre-
eclampsia might reflect early signs of placental hypoxia and of endothelial 
and angiogenic dysfunction (Hato T 2008). A third possibility could be that 
both metabolic alterations and placental hypoxia are interconnected and 
responsible for the rise in serum Angptl6 levels. 
Future studies with larger cohorts are needed to clarify the predictive role 
of Angptl6 in PIH. However, even with limited power, our study results 
strengthen the potential pole of angiogenic and angiogenic-like factors in the 
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pathogenesis of pre-eclampsia, but they showed no association between 
levels of the insulin sensitivity marker Angptl6 and insulin sensitivity during 
pregnancy.  
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8 CONCLUSIONS 
The following conclusions can be drawn from the five studies: 
 
 
Relatively overweight women who subsequently developed PIH had no 
evidence of insulin resistance, hyperandrogenism or inflammation at 24 or 
32 weeks of gestation compared with those who remained normotensive (I). 
 
In pre-eclampsia plasma noradrenaline levels were elevated (III). The rise in 
noradrenaline levels could already be seen at 32 weeks of gestation in women 
with subsequent PIH, at least in relatively overweight women (I).  
 
At 24 weeks of gestation, serum FABP4 concentrations and SBP after 10 
minutes’ standing in an orthostatic test were associated with the subsequent 
development of PIH (I). 
 
Serum Angptl6 levels in the second trimester of pregnancy were higher in 
women who subsequently developed PIH (II). 
 
In diurnal glucose profiles there was a greater increase in blood glucose from 
4 am to 8 am in women with GDM and chronic hypertension compared with 
women who remained normotensive (IV). 
 
At climacteric age, women with prior pre-eclampsia did not present with an 
increased incidence of metabolic syndrome, altered insulin resistance or 
hyperandrogenism (V).  
  
The present work supports the presence of sympathetic over-activity in 
hypertensive pregnancy. It is suggested that two regulators of insulin 
sensitivity, Angptl6 and FABP4, may have potential roles in the development 
of PIH. 
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